{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:50:35Z","timestamp":1794009035740,"version":"4.8.0"},"reference-count":553,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.vaccine.2021.03.079","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T09:57:42Z","timestamp":1621936662000},"page":"3696-3716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-8199","authenticated-orcid":false,"given":"Courtney","family":"Gidengil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Bidwell","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydne","family":"Newberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9290-4119","authenticated-orcid":false,"given":"Margaret","family":"Maglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-3929","authenticated-orcid":false,"given":"Owen","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9506-9734","authenticated-orcid":false,"given":"Jody","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneesa","family":"Motala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1597-5110","authenticated-orcid":false,"given":"Susanne","family":"Hempel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.03.079_b0005","first-page":"241","article-title":"Ten great public health achievements\u2013United States, 1900\u20131999","volume":"48","author":"Centers for Disease Control Prevention","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2021.03.079_b0010","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1016\/j.vaccine.2019.08.068","article-title":"Beliefs around childhood vaccines in the United States: A systematic review","volume":"37","author":"Gidengil","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0015","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-3852","article-title":"Parental hesitancy about routine childhood and influenza vaccinations: A national survey","volume":"146","author":"Kempe","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0020","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1016\/j.vaccine.2020.06.074","article-title":"Prevalence and characteristics of HPV vaccine hesitancy among parents of adolescents across the US","volume":"38","author":"Szilagyi","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0025","unstructured":"Centers for Disease Control and Prevention. Vaccination Coverage Among Adults in the United States, National Health Interview Survey, 2017. 2018"},{"key":"10.1016\/j.vaccine.2021.03.079_b0030","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.15585\/mmwr.mm6738a3","article-title":"Influenza and tdap vaccination coverage among pregnant women - United States, April 2018","volume":"67","author":"Kahn","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2021.03.079_b0035","doi-asserted-by":"crossref","first-page":"885","DOI":"10.15585\/mmwr.mm6840e1","article-title":"Vital Signs: Burden and Prevention of Influenza and Pertussis Among Pregnant Women and Infants - United States","volume":"68","author":"Lindley","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2021.03.079_b0040","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1542\/peds.2010-1722E","article-title":"Food and drug administration regulation and evaluation of vaccines","volume":"127","author":"Marshall","year":"2011","journal-title":"Pediatrics"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2021.03.079_b0045","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1542\/peds.2010-1722U","article-title":"Editors' introduction: Vaccine safety throughout the product life cycle","volume":"127","author":"Salmon","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0050","unstructured":"U.S Food and Drug Administration. Postmarketing Requirements and Commitments: Introduction; 2016."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2021.03.079_b0055","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pds.2323","article-title":"The food and drug administration's post-licensure rapid immunization safety monitoring program: strengthening the federal vaccine safety enterprise","volume":"21","author":"Nguyen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2021.03.079_b0060","unstructured":"Mini-Sentinel; 2011."},{"key":"10.1016\/j.vaccine.2021.03.079_b0065","unstructured":"U.S Food and Drug Administration. Vaccines; 2020."},{"key":"10.1016\/j.vaccine.2021.03.079_b0070","unstructured":"Sentinel. Vaccines, Blood, & Biologics Assessments."},{"key":"10.1016\/j.vaccine.2021.03.079_b0075","unstructured":"Centers for Disease Control and Prevention. Vaccine Safety Datalink (VSD); 2019"},{"key":"10.1016\/j.vaccine.2021.03.079_b0080","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/pds.613","article-title":"Vaccine safety datalink research G. The vaccine safety datalink project","volume":"10","author":"DeStefano","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2021.03.079_b0085","unstructured":"Centers for disease control and prevention. Clinical immunization safety assessment (CISA) project; 2020"},{"key":"10.1016\/j.vaccine.2021.03.079_b0090","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1016\/j.vaccine.2011.07.044","article-title":"Overview of the clinical consult case review of adverse events following immunization: clinical immunization safety assessment (CISA) network 2004\u20132009","volume":"29","author":"Williams","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0095","unstructured":"Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD); 2008."},{"key":"10.1016\/j.vaccine.2021.03.079_b0100","unstructured":"U.S Food and Drug Administration. Vaccines Licensed for Use in the United States."},{"key":"10.1016\/j.vaccine.2021.03.079_b0105","doi-asserted-by":"crossref","unstructured":"Centers for disease control and prevention. Immunization schedules: Table 1. Recommended adult immunization schedule for ages 19 years or older, United States, 2021","DOI":"10.1097\/01.JAA.0000735776.11981.1e"},{"key":"10.1016\/j.vaccine.2021.03.079_b0110","doi-asserted-by":"crossref","unstructured":"Centers for disease control and prevention. Immunization schedules: Table 1. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States; 2021.","DOI":"10.1097\/01.JAA.0000735776.11981.1e"},{"key":"10.1016\/j.vaccine.2021.03.079_b0115","first-page":"1","article-title":"Safety of vaccines used for routine immunization in the United States","author":"Maglione","year":"2014","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"key":"10.1016\/j.vaccine.2021.03.079_b0120","unstructured":"Institute of Medicine I. Adverse effects of vaccines: Evidence and causality. Washington, DC: The National Academy Press; 2011."},{"key":"10.1016\/j.vaccine.2021.03.079_b0125","unstructured":"Motala A, Hempel S, Gidengil C, Goetz M, Maglione M, Hall O, et al. Safety of vaccines used for routine immunization in the United States: An update. PROSPERO 2020 CRD42020180089 2020."},{"key":"10.1016\/j.vaccine.2021.03.079_b0130","unstructured":"Agency for healthcare research and quality. Safety of vaccines used for routine immunization in the United States: Research Protocol. April 6, 2020."},{"key":"10.1016\/j.vaccine.2021.03.079_b0135","unstructured":"Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org."},{"key":"10.1016\/j.vaccine.2021.03.079_b0140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.vaccine.2021.03.079_b0145","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1002\/sim.7411","article-title":"The Hartung-Knapp modification for random-effects meta-analysis: A useful refinement but are there any residual concerns?","volume":"36","author":"Jackson","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b0150","series-title":"The Development of the McHarm Quality Assessment Scale for adverse events: Delphi Consensus on important criteria for evaluating harms","author":"Santaguida","year":"2012"},{"key":"10.1016\/j.vaccine.2021.03.079_b0155","unstructured":"Methods guide for effectiveness and comparative effectiveness reviews. AHRQ Publication No. 10(14)-EHC063-EF. 2011\/03\/25 ed. Rockville, MD: Agency for Healthcare Research and Quality; January 2014."},{"key":"10.1016\/j.vaccine.2021.03.079_b0160","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.vaccine.2013.12.034","article-title":"Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants","volume":"32","author":"Abdelnour","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0165","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5530\/ami.2016.2.17","article-title":"Preventing pertussis in the early infant: Development and results of a prenatal vaccination program","volume":"3","author":"Acosta","year":"2016","journal-title":"Acta Medica Int"},{"key":"10.1016\/j.vaccine.2021.03.079_b0170","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/jtm.12164","article-title":"Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults","volume":"22","author":"Alberer","year":"2015","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b0175","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/jtm.12180","article-title":"Immunogenicity and safety of concomitant administration of a combined hepatitis A\/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults","volume":"22","author":"Alberer","year":"2015","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b0180","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/INF.0b013e31827b478d","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India","volume":"32","author":"Amdekar","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b0185","first-page":"1","article-title":"Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study","author":"Anez","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.03.079_b0190","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/INF.0000000000002832","article-title":"Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine in healthy meningococcal-Na\u00efve children 2\u20139 years of age: A phase III, randomized study","author":"Baccarini","year":"2020","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002844","article-title":"Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results","volume":"16","author":"Baker","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b0200","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.vaccine.2020.01.046","article-title":"The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines","volume":"38","author":"Baker","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0205","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1080\/21645515.2016.1182270","article-title":"Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study","volume":"12","author":"Bart","year":"2016","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0210","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.vaccine.2017.01.062","article-title":"Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2\u201349years","volume":"35","author":"Baxter","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0215","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/cid\/ciw607","article-title":"Acute demyelinating events following vaccines: a case-centered analysis","volume":"63","author":"Baxter","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/0194599816639043","article-title":"Sudden-onset sensorineural hearing loss after immunization: A case-centered analysis","volume":"155","author":"Baxter","year":"2016","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.vaccine.2021.03.079_b0225","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-0120","article-title":"Prenatal tetanus, diphtheria, acellular pertussis vaccination and autism spectrum disorder","volume":"142","author":"Becerra-Culqui","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0230","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/aje\/kwaa074","article-title":"The association of prenatal tetanus, diphtheria, and acellular pertussis (Tdap) vaccination with attention-deficit\/hyperactivity disorder","volume":"189","author":"Becerra-Culqui","year":"2020","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.03.079_b0235","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/1471-2334-13-224","article-title":"Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults","volume":"13","author":"Beran","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b0240","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1080\/21645515.2016.1157241","article-title":"Maternal and infant outcomes among women vaccinated against pertussis during pregnancy","volume":"12","author":"Berenson","year":"2016","journal-title":"Hum Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0245","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.vaccine.2009.10.104","article-title":"Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2\u201310 years of age","volume":"28","author":"Black","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0250","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/INF.0b013e31825687b0","article-title":"Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children","volume":"31","author":"Block","year":"2012","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b0255","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/INF.0000000000001405","article-title":"Lot-to-lot consistency, safety, tolerability and immunogenicity of an investigational hexavalent vaccine in US infants","volume":"36","author":"Block","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b0260","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.1016\/j.vaccine.2011.09.109","article-title":"A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults","volume":"29","author":"Block","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0265","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"The New England J Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b0270","article-title":"Clinical tolerance of in-neonatal intensive care unit administration of rotavirus vaccine","author":"Briggs-Steinberg","year":"2019","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.vaccine.2021.03.079_b0275","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/jpids\/piz035","article-title":"Does rotavirus vaccination affect longer-term intussusception risk in US infants?","volume":"9","author":"Burke","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2021.03.079_b0280","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/cid\/cit520","article-title":"Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program","volume":"57","author":"Carlin","year":"2013","journal-title":"Clin Infect Dis: An Official Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2021.03.079_b0285","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023118","article-title":"Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink","volume":"8","author":"Caspard","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2021.03.079_b0290","doi-asserted-by":"crossref","unstructured":"Chang L-J, Meng Y, Janosczyk H, Landolfi V, Talbot HK, Group QHDS. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults >=65years of age: A phase 3 randomized clinical trial. Vaccine. 2019;37:5825-34","DOI":"10.1016\/j.vaccine.2019.08.016"},{"key":"10.1016\/j.vaccine.2021.03.079_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2020.03.017","article-title":"A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States","author":"Chang","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0300","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jinf.2012.04.014","article-title":"Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan - A representative population-based comparative study","volume":"65","author":"Chang","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2021.03.079_b0305","article-title":"Pneumococcal pneumonia and the risk of stroke: a population-based follow-up study","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.03.079_b0310","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age","volume":"208","author":"Chlibek","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b0315","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/INF.0000000000000653","article-title":"Trends in Hospitalizations for Intussusception in California in Relationship to the Introduction of New Rotavirus Vaccines, 1985\u20132010","volume":"34","author":"Contopoulos-Ioannidis","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b0320","doi-asserted-by":"crossref","unstructured":"Cowling BJ, Perera RAPM, Valkenburg SA, Leung NHL, Iuliano AD, Tam YH, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis: An Official Publ Infect Dis Soc Am; 2019.","DOI":"10.1093\/cid\/ciz1034"},{"key":"10.1016\/j.vaccine.2021.03.079_b0325","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"The New Engl J Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b0330","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.vaccine.2018.02.013","article-title":"Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study","volume":"36","author":"Cutland","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0335","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/cid\/cit428","article-title":"Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial","volume":"57","author":"Dagan","year":"2013","journal-title":"Clin Infect Dis: An Official Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2021.03.079_b0340","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1016\/j.vaccine.2014.03.063","article-title":"Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine","volume":"32","author":"Daley","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0345","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.vaccine.2015.02.070","article-title":"Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad) administered concomitantly with a booster dose of a hexavalent vaccine in 12\u201323-month-old infants","volume":"33","author":"Deichmann","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0350","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jamapediatrics.2015.0418","article-title":"Adverse events after routine immunization of extremely low-birth-weight infants","volume":"169","author":"DeMeo","year":"2015","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2021.03.079_b0355","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1016\/j.vaccine.2017.05.041","article-title":"Maternal Tdap vaccination and risk of infant morbidity","volume":"35","author":"DeSilva","year":"2017","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2021.03.079_b0360","doi-asserted-by":"crossref","first-page":"A117","DOI":"10.1016\/j.vaccine.2014.03.069","article-title":"Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1\u2013G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants","volume":"32","author":"Dhingra","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0365","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1016\/j.vaccine.2020.06.013","article-title":"Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study","volume":"38","author":"Dhingra","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0370","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/infdis\/jit091","article-title":"A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3\u201317 years","volume":"207","author":"Domachowske","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b0375","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-1808","article-title":"Near real-time surveillance to assess the safety of the 9-valent human papillomavirus vaccine","volume":"144","author":"Donahue","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.2016-0320","article-title":"Febrile seizure risk after vaccination in children 6 to 23 months","volume":"138","author":"Duffy","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0385","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa1608862","article-title":"Efficacy of recombinant influenza vaccine in adults 50 years of age or older","volume":"376","author":"Dunkle","year":"2017","journal-title":"The New Engl J Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b0390","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/infdis\/jix478","article-title":"Randomized comparison of immunogenicity and safety of quadrivalent recombinant versus inactivated influenza vaccine in healthy adults 18\u201349 years of age","volume":"216","author":"Dunkle","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b0395","unstructured":"Dynavax Technologies C. Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV\u2122, Compared to Engerix-B\u00ae Vaccine; 2015"},{"key":"10.1016\/j.vaccine.2021.03.079_b0400","unstructured":"Dynavax Technologies Corporation. Safety and Efficacy of HEPLISAV\u2122 Hepatitis B Virus Vaccine Compared With Engerix-B\u00ae Vaccine; 2006"},{"key":"10.1016\/j.vaccine.2021.03.079_b0405","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13343","article-title":"A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients","volume":"22","author":"Eriksson","year":"2020","journal-title":"Transplant Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b0410","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.vaccine.2015.01.005","article-title":"Intussusception risk after RotaTeq vaccination: evaluation from worldwide spontaneous reporting data using a self-controlled case series approach","volume":"33","author":"Escolano","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0415","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.vaccine.2019.10.021","article-title":"Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults","volume":"38","author":"Essink","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0420","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1016\/j.vaccine.2020.04.067","article-title":"Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in >\/=56-year-olds: A Phase III randomized study","volume":"38","author":"Esteves-Jaramillo","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0425","unstructured":"Euctr Outside EU\/EEA. Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age. 2014."},{"key":"10.1016\/j.vaccine.2021.03.079_b0430","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jped.2015.06.008","article-title":"Hospital-based surveillance of intussusception among infants","volume":"92","author":"Fernandes","year":"2016","journal-title":"Jornal de pediatria"},{"key":"10.1016\/j.vaccine.2021.03.079_b0435","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13075-015-0663-9","article-title":"Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases\u2013a longitudinal study","volume":"17","author":"Fischer","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.vaccine.2021.03.079_b0440","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1016\/j.vaccine.2019.02.053","article-title":"A case-control study of risk factors for intussusception among infants in eastern France after the introduction of the rotavirus vaccine","volume":"37","author":"Fotso Kamdem","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0445","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1128\/CVI.00176-12","article-title":"Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults","volume":"19","author":"Frenck","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.03.079_b0450","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1016\/j.vaccine.2014.07.013","article-title":"Comparison of the safety and immunogenicity of an MF59-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0455","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and immunogenicity of a 9-valent HPV vaccine in females 12\u201326 years of age who previously received the quadrivalent HPV vaccine","volume":"33","author":"Garland","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0460","first-page":"231","article-title":"Immunogenicity and safety of combined tetanus, reduced diphtheria, acellular pertussis vaccine when co-administered with quadrivalent meningococcal conjugate and human papillomavirus vaccines in healthy adolescents","volume":"5","author":"Gasparini","year":"2014","journal-title":"J Vaccines Vaccin"},{"key":"10.1016\/j.vaccine.2021.03.079_b0465","article-title":"A longitudinal cohort study of childhood MMR vaccination and seizure disorder among American children","author":"Geier","year":"2020","journal-title":"Brain and Dev"},{"key":"10.1016\/j.vaccine.2021.03.079_b0470","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1016\/j.vaccine.2018.09.057","article-title":"Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial","volume":"36","author":"Gilca","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0475","first-page":"E1","article-title":"Association between rotavirus vaccination and type 1 diabetes in children","author":"Glanz","year":"2020","journal-title":"JAMAPediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0480","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1016\/j.vaccine.2020.04.056","article-title":"Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety","volume":"38","author":"Glover","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0485","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/INF.0000000000000254","article-title":"Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age","volume":"33","author":"Greenberg","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b0490","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.vaccine.2012.11.074","article-title":"Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults","volume":"31","author":"Greenberg","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0495","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1080\/21645515.2017.1344375","article-title":"Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older","volume":"13","author":"Greenberg","year":"2017","journal-title":"Hum Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0500","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.vaccine.2014.02.002","article-title":"Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60\u201364 years of age","volume":"32","author":"Greenberg","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0505","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1016\/j.vaccine.2018.07.011","article-title":"Pertussis immunisation in pregnancy safety (PIPS) study: A retrospective cohort study of safety outcomes in pregnant women vaccinated with Tdap vaccine","volume":"36","author":"Griffin","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0510","doi-asserted-by":"crossref","unstructured":"Groome MJ, Tate JE, Arnold M, Chitnis M, Cox S, de Vos C, et al. Evaluation of intussusception after oral monovalent rotavirus vaccination in South Africa. Clin Infect Dis: An Official Publ Infect Dis Soc Am; 2019.","DOI":"10.1093\/cid\/ciz431"},{"key":"10.1016\/j.vaccine.2021.03.079_b0515","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.vaccine.2020.01.009","article-title":"Safety of tetanus, diphtheria, and acellular pertussis vaccination among pregnant active duty U.S. military women","volume":"38","author":"Hall","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0520","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jpids\/pix113","article-title":"Randomized controlled trial of the safety and immunogenicity of revaccination with tetanus-diphtheria-acellular pertussis vaccine (tdap) in adults 10 years after a previous dose","volume":"8","author":"Halperin","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2021.03.079_b0525","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/cid\/ciy244","article-title":"A Randomized controlled trial of the safety and immunogenicity of tetanus, diphtheria, and acellular pertussis vaccine immunization during pregnancy and subsequent infant immune response","volume":"67","author":"Halperin","year":"2018","journal-title":"Clin Infect Diseases : An Official Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2021.03.079_b0530","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1016\/j.vaccine.2016.06.062","article-title":"Safety of DTaP-IPV\/Hib vaccine administered routinely to infants and toddlers","volume":"34","author":"Hansen","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0535","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.vaccine.2018.02.107","article-title":"Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children","volume":"36","author":"Hansen","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0540","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.1016\/j.vaccine.2017.09.032","article-title":"Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine","volume":"35","author":"Hansen","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0545","first-page":"65","article-title":"Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: a phase III randomized, multicenter, double-blind clinical trial","volume":"41","author":"Hartvickson","year":"2015","journal-title":"Int J Infect Dis: IJID : Official Publ Int Soc Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b0550","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/ped.13506","article-title":"Survey of rotavirus-associated severe complications in Aichi Prefecture","volume":"60","author":"Hattori","year":"2018","journal-title":"Pediatr Int"},{"key":"10.1016\/j.vaccine.2021.03.079_b0555","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/21645515.2016.1240846","article-title":"Assessing the risk of intussusception and rotavirus vaccine safety in Canada","volume":"13","author":"Hawken","year":"2017","journal-title":"Hum Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0560","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1016\/j.vaccine.2013.05.068","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40\u201370 years of age","volume":"31","author":"Heyward","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0565","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1080\/21645515.2018.1450123","article-title":"Safety study of live, oral human rotavirus vaccine: A cohort study in United States health insurance plans","volume":"14","author":"Hoffman","year":"2018","journal-title":"Hum Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0570","article-title":"The impact of hepatitis B vaccination status on the risk of diabetes, implicating diabetes risk reduction by successful vaccination","volume":"10","author":"Huang","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.03.079_b0575","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1016\/j.vaccine.2020.07.038","article-title":"Intussusception and Kawasaki disease after rotavirus vaccination in Taiwanese infants","volume":"38","author":"Huang","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0580","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16\u201326 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.vaccine.2021.03.079_b0585","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1086\/656587","article-title":"Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study","volume":"51","author":"Hung","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b0590","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M18-2101","article-title":"Measles, mumps, rubella vaccination and autism: a nationwide cohort study","volume":"170","author":"Hviid","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b0595","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.4161\/hv.24846","article-title":"Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"9","author":"Iwata","year":"2013","journal-title":"Hum Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0600","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0605","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1001\/jama.2015.3077","article-title":"Autism occurrence by MMR vaccine status among US children with older siblings with and without autism","volume":"313","author":"Jain","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.03.079_b0610","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4161\/hv.27998","volume":"10","author":"Juergens","year":"2014","journal-title":"Hum Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0615","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1016\/j.vaccine.2015.08.011","article-title":"Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease","volume":"33","author":"Kantso","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0620","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.vaccine.2015.12.046","article-title":"Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007\u20132013","volume":"34","author":"Kharbanda","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0625","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/1471-2334-13-343","article-title":"Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >=18 years","volume":"13","author":"Kieninger","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b0630","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/INF.0b013e3182748bb6","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines","volume":"32","author":"Kim","year":"2013","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b0635","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/21645515.2020.1733868","article-title":"Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study","volume":"16","author":"Kirstein","year":"2020","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0640","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2010-0665","article-title":"Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures","volume":"126","author":"Klein","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0645","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1542\/peds.2014-1822","article-title":"Safety of measles-containing vaccines in 1-year-old children","volume":"135","author":"Klein","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0650","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"The New Engl J Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b0655","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jamaneurol.2014.2633","article-title":"Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases","volume":"71","author":"Langer-Gould","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.vaccine.2021.03.079_b0660","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/infdis\/jit263","article-title":"Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children","volume":"208","author":"Langley","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b0665","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/jpids\/piu098","article-title":"Immunogenicity and reactogenicity of an inactivated quadrivalent influenza vaccine administered intramuscularly to children 6 to 35 months of age in 2012\u20132013: A randomized, double-blind, controlled, multicenter, multicountry, clinical trial","volume":"4","author":"Langley","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2021.03.079_b0670","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1016\/j.vaccine.2017.06.071","article-title":"Prenatal Tdap immunization and risk of maternal and newborn adverse events","volume":"35","author":"Layton","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0675","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/ppe.12496","article-title":"Rotavirus vaccination and short-term risk of adverse events in US infants","volume":"32","author":"Layton","year":"2018","journal-title":"Paediatr Perinat Epidemiol"},{"key":"10.1016\/j.vaccine.2021.03.079_b0680","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.vaccine.2016.01.033","article-title":"Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea\u2013A randomised trial","volume":"34","author":"Lee","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0685","first-page":"204","article-title":"Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults","volume":"28","author":"Lee","year":"2014","journal-title":"Int J Infect Dis: IJID : Official Publ Int Soc Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b0690","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fpsyt.2017.00003","article-title":"Temporal association of certain neuropsychiatric disorders following vaccination of children and adolescents: a pilot case-control study","volume":"8","author":"Leslie","year":"2017","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.vaccine.2021.03.079_b0695","article-title":"Impact of 23-valent pneumococcal polysaccharide vaccination on the frequency of pneumonia-related hospitalization and survival in elderly patients with prostate cancer: A seven-year nationwide matched cohort study","author":"Li","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2021.03.079_b0700","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/pds.3996","article-title":"Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013\u20132014 and 2014\u20132015 seasons","volume":"25","author":"Li","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2021.03.079_b0705","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4161\/hv.26319","article-title":"Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China","volume":"10","author":"Li","year":"2014","journal-title":"Hum Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0710","article-title":"Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot","volume":"11","author":"Lombardi","year":"2016","journal-title":"Prospective Controlled Study PloS one"},{"key":"10.1016\/j.vaccine.2021.03.079_b0715","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.vaccine.2019.11.055","article-title":"A study to evaluate the immunogenicity and shedding of live attenuated influenza vaccine strains in children 24\u2013<48 months of age","volume":"38","author":"Mallory","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0720","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/irv.12555","article-title":"The safety and efficacy of quadrivalent live attenuated influenza vaccine in Japanese children aged 2\u201318 years: Results of two phase 3 studies","volume":"12","author":"Mallory","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2021.03.079_b0725","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1016\/j.vaccine.2018.05.110","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults \u226550 years of age: a randomized trial","volume":"36","author":"Mar\u00e9chal","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0730","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1542\/peds.2014-4102","article-title":"Immunogenicity, safety, and tolerability of a hexavalent vaccine in infants","volume":"136","author":"Marshall","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0735","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.vaccine.2018.11.038","article-title":"Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders","volume":"37","author":"McClure","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0740","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.1016\/j.vaccine.2020.06.078","article-title":"Impact of rotavirus vaccination on intussusception hospital admissions in England","volume":"38","author":"McGeoch","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0745","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1016\/j.vaccine.2017.08.081","article-title":"Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial","volume":"35","author":"Mo","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0750","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/AOG.0000000000000862","article-title":"Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination","volume":"125","author":"Morgan","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2021.03.079_b0755","doi-asserted-by":"crossref","DOI":"10.2196\/14791","article-title":"Participant-centered online active surveillance for adverse events following vaccination in a large clinical trial: feasibility and usability study","volume":"21","author":"Munnoch","year":"2019","journal-title":"J Medical Internet Res"},{"key":"10.1016\/j.vaccine.2021.03.079_b0760","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1001\/jama.2014.3633","article-title":"Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial","volume":"311","author":"Munoz","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.03.079_b0765","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-0943","article-title":"Primary ovarian insufficiency and adolescent vaccination","volume":"142","author":"Naleway","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0770","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/aje\/kws317","article-title":"Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study","volume":"177","author":"Nelson","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.03.079_b0775","first-page":"1","article-title":"Retrospective multicenter matched case-control study on the risk factors for intussusception in infants less than 1 year of age with a special focus on rotavirus vaccines - the German Intussusception Study","author":"Oberle","year":"2020","journal-title":"Hum Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0780","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.vaccine.2013.11.017","article-title":"Evaluating the clinical effectiveness of pneumococcal vaccination in preventing myocardial infarction: The CAPAMIS study, three-year follow-up","volume":"32","author":"Ochoa-Gondar","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0785","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1016\/j.vaccine.2017.09.012","volume":"35","author":"Ofori-Anyinam","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0790","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.vaccine.2016.01.044","article-title":"A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults","volume":"34","author":"Ostergaard","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0795","doi-asserted-by":"crossref","unstructured":"Perez JZV, Aranda JMR, de la O Cavazos M, Osuna MDZ, Davila JP, Elizondo MRB, et al. Randomized clinical trial of the safety and immunogenicity of the Tdap vaccine in pregnant Mexican women. Hum Vaccines & Immunotherapeutics. 2017;13:128-35.","DOI":"10.1080\/21645515.2016.1232786"},{"key":"10.1016\/j.vaccine.2021.03.079_b0800","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1016\/j.vaccine.2019.05.041","article-title":"Surveillance for Guillain-Barre syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017\u20132018 season","volume":"37","author":"Perez-Vilar","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0805","article-title":"Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial","author":"Perrett","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0810","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/vaccines7040147","article-title":"A retrospective cohort study of safety outcomes in new zealand infants exposed to tdap vaccine in utero","volume":"7","author":"Petousis-Harris","year":"2019","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2021.03.079_b0815","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/21645515.2015.1080395","article-title":"Concomitant use of VAQTA\u00ae with PedvaxHIB\u00ae and Infanrix\u00ae in 12 to 17 month old children","volume":"12","author":"Petrecz","year":"2016","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0820","unstructured":"Pfizer. Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults. https:\/\/ClinicalTrials.gov\/show\/NCT00427895; 2007."},{"key":"10.1016\/j.vaccine.2021.03.079_b0825","doi-asserted-by":"crossref","first-page":"7313","DOI":"10.1016\/j.vaccine.2007.08.039","article-title":"Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly","volume":"25","author":"Puig-Barbera","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0830","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b0835","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1016\/j.vaccine.2018.04.034","volume":"36","author":"Rivera","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0840","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/INF.0000000000000463","article-title":"Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18\u201347 months of age","volume":"33","author":"Rodriguez Weber","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.vaccine.2021.03.079_b0845","article-title":"Lower incidence rate of type 1 diabetes after receipt of the rotavirus vaccine in the United States","volume":"2019","author":"Rogers","year":"2001","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2021.03.079_b0850","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1016\/j.vaccine.2019.04.086","article-title":"Impact of rotavirus vaccination on childhood hospitalizations for seizures: Heterologous or unforeseen direct vaccine effects?","volume":"37","author":"Salas","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0855","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1080\/21645515.2019.1627161","article-title":"Safety of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine when administered during pregnancy as part of the maternal immunization program in Brazil: a single center, observational, retrospective, cohort study","volume":"15","author":"Sancovski","year":"2019","journal-title":"Hum Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0860","unstructured":"Sanofi Pasteur aSC, Sanofi. Safety and Immunogenicity of Fluzone\u00ae Quadrivalent, Flublok\u00ae Quadrivalent, and Fluzone\u00ae High-Dose, Influenza Vaccines, 2018-2019 Formulations. 2018."},{"key":"10.1016\/j.vaccine.2021.03.079_b0865","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.03.079_b0870","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/infdis\/jix481","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older","volume":"216","author":"Schwarz","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b0875","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1016\/j.vaccine.2011.05.031","article-title":"A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged >=65 years","volume":"29","author":"Schwarz","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0880","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/INF.0000000000001072","article-title":"Immunogenicity, tolerability and safety in adolescents of bivalent rLP2086, a meningococcal serogroup b vaccine, coadministered with quadrivalent human papilloma virus vaccine","volume":"35","author":"Senders","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b0885","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7774\/cevr.2017.6.1.38","article-title":"Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly","volume":"6","author":"Seo","year":"2017","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.vaccine.2021.03.079_b0890","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jpeds.2013.06.021","article-title":"Tetanus, diphtheria, acellular pertussis vaccine during pregnancy: pregnancy and infant health outcomes","volume":"163","author":"Shakib","year":"2013","journal-title":"J Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0895","article-title":"Safety and efficacy of simultaneous inoculations of pneumococcal and influenza vaccines in patients with coronary artery disease","author":"Shimada","year":"2020","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.vaccine.2021.03.079_b0900","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1080\/21645515.2015.1030550","article-title":"Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults","volume":"11","author":"Shiramoto","year":"2015","journal-title":"Hum Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0905","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.vaccine.2014.01.029","article-title":"Influenza and pneumococcal vaccination and risk of stroke or transient ischaemic attack-matched case control study","volume":"32","author":"Siriwardena","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0910","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2016.11.047","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in 60-year-old adults","volume":"35","author":"Song","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0915","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1186\/s12879-018-3479-9","article-title":"Immunogenicity and safety of a tetanus-diphtheria vaccine and a 13-valent pneumococcal conjugate vaccine after concomitant vaccination in >= 50-year-old adults","volume":"18","author":"Song","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b0920","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1016\/j.vaccine.2015.05.003","article-title":"Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults","volume":"33","author":"Song","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0925","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/jamapediatrics.2013.4469","article-title":"Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine","volume":"168","author":"Stockwell","year":"2014","journal-title":"JAMA Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0930","first-page":"e7","article-title":"Assessing fever frequency after pediatric live attenuated versus inactivated influenza vaccination","volume":"6","author":"Stockwell","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2021.03.079_b0935","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1016\/j.vaccine.2016.04.050","article-title":"The risk of intussusception following monovalent rotavirus vaccination in England: A self-controlled case-series evaluation","volume":"34","author":"Stowe","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0940","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1016\/j.vaccine.2019.08.001","article-title":"The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged >=50 years: A randomized trial","volume":"37","author":"Strezova","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0945","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1016\/j.vaccine.2018.05.012","article-title":"Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group","volume":"36","author":"Svensson","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0950","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/INF.0b013e3182717edf","article-title":"Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study","volume":"32","author":"Tapiero","year":"2013","journal-title":"Pediatric Infect Disease J"},{"key":"10.1016\/j.vaccine.2021.03.079_b0955","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1713909","article-title":"Evaluation of intussusception after monovalent rotavirus vaccination in Africa","volume":"378","author":"Tate","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b0960","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-1082","article-title":"Intussusception rates before and after the introduction of rotavirus vaccine","volume":"138","author":"Tate","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0965","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/21645515.2018.1533777","article-title":"Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial","volume":"15","author":"Thompson","year":"2019","journal-title":"Hum Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b0970","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/pai.12391","article-title":"Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination","volume":"26","author":"Timmermann","year":"2015","journal-title":"Pediatric Allergy and Immunology : Official Publication of the Eur Soc Pediatric Allergy Immunology"},{"key":"10.1016\/j.vaccine.2021.03.079_b0975","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.vaccine.2014.01.022","article-title":"Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged >=18 years: a phase III, randomized trial","volume":"32","author":"Tinoco","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0980","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/INF.0000000000000819","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with DTaP vaccine in healthy infants in Japan","volume":"34","author":"Togashi","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b0985","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.vaccine.2017.02.066","article-title":"Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study","volume":"35","author":"Treanor","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b0990","first-page":"22","article-title":"Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers","volume":"26","author":"Tregnaghi","year":"2014","journal-title":"Int J Infect Dis: IJID : Official Publication of the Int Soc Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b0995","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2084","article-title":"Safety of quadrivalent meningococcal conjugate vaccine in 11- to 21-year-olds","volume":"139","author":"Tseng","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b1000","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.vaccine.2013.03.040","article-title":"Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children","volume":"31","author":"Tseng","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b1005","article-title":"Pneumococcal Conjugate vaccine safety in elderly adults","author":"Tseng","year":"20185100","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b1010","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1097\/INF.0000000000000441","article-title":"Impact of rotavirus vaccination in Germany: rotavirus surveillance, hospitalization, side effects and comparison of vaccines","volume":"33","author":"Uhlig","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b1015","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.vaccine.2014.12.036","article-title":"Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder","volume":"33","author":"Uno","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b1020","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/INF.0000000000001600","article-title":"Rotavirus vaccination and the risk of celiac disease or type 1 diabetes in finnish children at early life","volume":"36","author":"Vaarala","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b1025","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1016\/j.vaccine.2016.06.056","article-title":"A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men","volume":"34","author":"Van Damme","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b1030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cmi.2017.05.016","article-title":"Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study","volume":"24","author":"Vandecasteele","year":"2018","journal-title":"Clin Microbiology Infection : Official Publi Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b1035","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/INF.0000000000000773","article-title":"A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus gardasil in 9\u201315-year-old girls","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b1040","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(07)61744-9","article-title":"Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study","volume":"370","author":"Vesikari","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.03.079_b1045","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jpids\/piv064","article-title":"Immunogenicity, safety, and tolerability of bivalent rLP2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, and acellular pertussis and inactivated poliomyelitis vaccines to healthy adolescents","volume":"5","author":"Vesikari","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2021.03.079_b1050","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12879-018-3096-7","article-title":"Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study","volume":"18","author":"Vila-Corcoles","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b1055","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/aje\/kwt078","article-title":"Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy","volume":"178","author":"Villa","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.03.079_b1060","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-1909","article-title":"Fever after influenza, diphtheria-tetanus-acellular pertussis, and pneumococcal vaccinations","volume":"145","author":"Walter","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b1065","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jpids\/piv041","article-title":"Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in US children 6\u201335 Months of age during 2013\u20132014: results from a phase II randomized trial","volume":"5","author":"Wang","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2021.03.079_b1070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/pds.4399","article-title":"Methods for addressing \u201cinnocent bystanders\u201d when evaluating safety of concomitant vaccines","volume":"27","author":"Wang","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2021.03.079_b1075","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1303164","article-title":"Intussusception risk after rotavirus vaccination in U.S. infants","volume":"370","author":"Yih","year":"2014","journal-title":"The New Engl J Med"},{"issue":"163\u20138","key":"10.1016\/j.vaccine.2021.03.079_b1080","article-title":"Intussusception and monovalent rotavirus vaccination in singapore: self-controlled case series and risk-benefit study","volume":"167","author":"Yung","year":"2015","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2021.03.079_b1085","doi-asserted-by":"crossref","first-page":"14705","DOI":"10.1038\/s41598-019-51137-5","article-title":"Kawasaki Disease following administration of 13-valent pneumococcal conjugate vaccine in young children","volume":"9","author":"Yung","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2021.03.079_b1090","first-page":"122","article-title":"Associations between pneumococcal vaccination and adverse outcomes in patients with suspected acute coronary syndrome","author":"Zahid","year":"2012","journal-title":"Adv Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b1095","doi-asserted-by":"crossref","unstructured":"Erratum: v72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study (The Lancet (2012) 379 (617-624)). Lancet. 2015;385:1728","DOI":"10.1016\/S0140-6736(11)61713-3"},{"key":"10.1016\/j.vaccine.2021.03.079_b1100","unstructured":"AstraZeneca. A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years; 2015."},{"key":"10.1016\/j.vaccine.2021.03.079_b1105","unstructured":"Sint-Jan AZ, Pfizer AV. 13 valent pneumococcal conjugate vaccine in chronic dialysis patients; 2013"},{"key":"10.1016\/j.vaccine.2021.03.079_b1110","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/aje\/kwu322","article-title":"A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program","volume":"181","author":"Baker","year":"2015","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.03.079_b1115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/cid\/ciw224","article-title":"Case-centered analysis of optic neuritis after vaccines","volume":"63","author":"Baxter","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b1120","unstructured":"Clinical Trials Registry-India. CTRI\/2012\/07\/002820: A study to evaluate safety of Rotavirus vaccine in Healthy Adult Volunteers followed by Safety, Tolerability and Immunogenicity evaluation in healthy infants. July 31, 2013."},{"key":"10.1016\/j.vaccine.2021.03.079_b1125","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2020.1741312","article-title":"Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials","author":"Colindres","year":"2020","journal-title":"Hum Vaccines and Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b1130","unstructured":"Columbia University, Centers for Disease Control Prevention. FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging; 2011."},{"key":"10.1016\/j.vaccine.2021.03.079_b1135","unstructured":"Columbia University, Centers for Disease Control Prevention. Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014; 2013."},{"key":"10.1016\/j.vaccine.2021.03.079_b1140","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/infdis\/jiaa255","article-title":"Comparative reactogenicity of enhanced influenza vaccines in older adults","volume":"222","author":"Cowling","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b1145","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1001\/jama.2016.14432","article-title":"Tdap vaccination during pregnancy and microcephaly and other structural birth defects in offspring","volume":"316","author":"DeSilva","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.03.079_b1150","first-page":"e72","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine candidate when coadministered with a 23-valent pneumococcal polysaccharide vaccine in adults 50 years of age or older: a phase iii, randomized clinical trial","volume":"58","author":"Dezure","year":"2018","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.vaccine.2021.03.079_b1155","unstructured":"Dynavax Technologies Corporation. Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine; 2010"},{"key":"10.1016\/j.vaccine.2021.03.079_b1160","unstructured":"Euctr BE. Evaluation of the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals\u2019 Quadrivalent Influenza Vaccine Influsplit\u2122 Tetra (Fluarix\u2122 Tetra) (GSK2321138A) when co-administered with Pneumovax\u2122 23 in adults 50 years of age and older. http:\/\/wwwwhoint\/trialsearch\/Trial2aspx?TrialID=EUCTR2014-001118-24-BE. 2014."},{"key":"10.1016\/j.vaccine.2021.03.079_b1165","unstructured":"Euctr CZ. Immunogenicity and safety study of Boostrix in pregnant women. http:\/\/wwwwhoint\/trialsearch\/Trial2aspx?TrialID=EUCTR2014-001119-38-CZ. 2015."},{"key":"10.1016\/j.vaccine.2021.03.079_b1170","unstructured":"Everett D. Hepatitis B Vaccine (Recombinant), Adjuvanted (Heplisav-B): Review of Safety. Vaccines and Related Biological Products Advisory Committee Meeting: U.S. Food & Drug Administration; July 28, 2017."},{"key":"10.1016\/j.vaccine.2021.03.079_b1175","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/infdis\/jiy133","article-title":"Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine: subgroup analysis of participants from asian countries","volume":"218","author":"Garland","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b1180","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ygyno.2019.03.253","article-title":"Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population","volume":"154","author":"Giuliano","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2021.03.079_b1185","unstructured":"GlaxoSmithKline. To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines. https:\/\/ClinicalTrials.gov\/show\/NCT00140686; 2004."},{"key":"10.1016\/j.vaccine.2021.03.079_b1190","unstructured":"GlaxoSmithKline. Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults; 2008."},{"key":"10.1016\/j.vaccine.2021.03.079_b1195","unstructured":"GlaxoSmithKline. Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years; 2009."},{"key":"10.1016\/j.vaccine.2021.03.079_b1200","unstructured":"GlaxoSmithKline. Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children. https:\/\/ClinicalTrials.gov\/show\/NCT00985790; 2009."},{"key":"10.1016\/j.vaccine.2021.03.079_b1205","unstructured":"GlaxoSmithKline. Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A). 2010."},{"key":"10.1016\/j.vaccine.2021.03.079_b1210","unstructured":"GlaxoSmithKline. A study to evaluate the safety and immunogenicity of GSK biologicals' seasonal influenza vaccine in children; 2010."},{"key":"10.1016\/j.vaccine.2021.03.079_b1215","unstructured":"GlaxoSmithKline. A study to evaluate the safety and immunogenicity of GSK biologicals' seasonal influenza vaccine in adults; 2010."},{"key":"10.1016\/j.vaccine.2021.03.079_b1220","unstructured":"GlaxoSmithKline. Study to assess the efficacy, immunogenicity and safety of liquid human rotavirus vaccine, in healthy chinese infants; 2010."},{"key":"10.1016\/j.vaccine.2021.03.079_b1225","unstructured":"GlaxoSmithKline. Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older; 2010."},{"key":"10.1016\/j.vaccine.2021.03.079_b1230","unstructured":"GlaxoSmithKline. Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children. https:\/\/ClinicalTrials.gov\/show\/NCT01196988; 2010."},{"key":"10.1016\/j.vaccine.2021.03.079_b1235","unstructured":"GlaxoSmithKline. Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age; 2012."},{"key":"10.1016\/j.vaccine.2021.03.079_b1240","unstructured":"GlaxoSmithKline. Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix\u00ae in Subjects Between 11 and 25 Years of Age; 2014."},{"key":"10.1016\/j.vaccine.2021.03.079_b1245","unstructured":"GlaxoSmithKline. Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age; 2014."},{"key":"10.1016\/j.vaccine.2021.03.079_b1250","unstructured":"GlaxoSmithKline. Study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) biologicals' herpes zoster vaccine GSK1437173A When co-administered with GSK biologicals' seasonal influenza vaccine GSK2321138A in adults aged 50 years and older; 2014."},{"key":"10.1016\/j.vaccine.2021.03.079_b1255","unstructured":"GlaxoSmithKline. Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) biologicals' herpes zoster subunit (HZ\/su) vaccine (GSK1437173A) when co-administered with GSK biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix\u00ae) in adults aged 50 years and older; 2015."},{"key":"10.1016\/j.vaccine.2021.03.079_b1260","unstructured":"GlaxoSmithKline. Evaluation of the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' quadrivalent influenza vaccine influsplit\u2122 tetra (Fluarix\u2122 Tetra) (GSK2321138A) when co-administered with pneumovax\u2122 23 in adults 50 years of age and older; 2015."},{"key":"10.1016\/j.vaccine.2021.03.079_b1265","unstructured":"GlaxoSmithKline. Study to evaluate immunogenicity and safety study of GSK biologicals' herpes zoster (HZ) vaccine GSK1437173A when co-administered with pneumovax 23\u2122 in adults aged 50 years and older; 2015."},{"key":"10.1016\/j.vaccine.2021.03.079_b1270","unstructured":"GlaxoSmithKline. A post-marketing, observational, retrospective study to assess the safety of refortrixTM (Tdap) when administered during pregnancy in a maternal immunization program in Brazil; 2017."},{"key":"10.1016\/j.vaccine.2021.03.079_b1275","unstructured":"GlaxoSmithKline. Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals' Boostrix\u2122 Vaccine in Pregnant Women; 2017."},{"key":"10.1016\/j.vaccine.2021.03.079_b1280","unstructured":"GlaxoSmithKline. Study to evaluate efficacy, safety and immunogenicity of GlaxoSmithKline (GSK) biologicals' herpes zoster (HZ) vaccine GSK1437173A in adults aged 70 years and older; 2017."},{"key":"10.1016\/j.vaccine.2021.03.079_b1285","unstructured":"GlaxoSmithKline. Immunogenicity and safety study of infanrix hexa in healthy infants born to mothers vaccinated with boostrix\u2122 during pregnancy or immediately post-delivery; 2018."},{"key":"10.1016\/j.vaccine.2021.03.079_b1290","unstructured":"GlaxoSmithKline. Evaluation of immunogenicity and safety of a booster dose of infanrix hexa\u2122 in healthy infants born to mothers vaccinated with boostrix\u2122 during pregnancy or immediately post-delivery; 2019."},{"key":"10.1016\/j.vaccine.2021.03.079_b1295","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1016\/j.vaccine.2017.07.017","article-title":"Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine","volume":"35","author":"Guevara","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b1300","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/21645515.2018.1514227","article-title":"Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine","volume":"15","author":"Guevara","year":"2019","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b1305","doi-asserted-by":"crossref","first-page":"e1492","DOI":"10.1542\/peds.2013-3429","article-title":"Timely versus delayed early childhood vaccination and seizures","volume":"133","author":"Hambidge","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b1310","article-title":"Study of the immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine (MENACYW-TT) when co-administered with other vaccines in healthy adolescents","author":"Hedrick","year":"20185570","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b1315","article-title":"Immunogenicity and safety of a booster dose of a quadrivalent meningococcal conjugate vaccine (menacyw-TT) in adolescents and adults","author":"Hedrick","year":"20196959","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b1320","unstructured":"Helsinki University Central Hospital, Tampere University Hospital. Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients. https:\/\/ClinicalTrials.gov\/show\/NCT01781871; 2013."},{"key":"10.1016\/j.vaccine.2021.03.079_b1325","unstructured":"Hospital Universitario Dr. Jose E. Gonzalez. Immunogenicity and safety of an acellular DPT vaccine during pregnancy; 2011"},{"key":"10.1016\/j.vaccine.2021.03.079_b1330","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.vaccine.2018.03.067","article-title":"Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults","volume":"36","author":"Hyer","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b1335","doi-asserted-by":"crossref","first-page":"5854","DOI":"10.1016\/j.vaccine.2019.08.005","article-title":"Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg\/CpG 1018, in persons with diabetes mellitus aged 60\u201370years","volume":"37","author":"Hyer","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b1340","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy210.2115","article-title":"Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered in individuals 56 years of age and older","volume":"5","author":"Jeanfreau","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b1345","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b1350","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/S0016-5085(15)30589-8","article-title":"Specific antibody response to two pneumococcal vaccines in crohn's disease patients treated with immunosuppressive drugs alone or in combination with biological therapy","volume":"148","author":"Kantso","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2021.03.079_b1355","unstructured":"Karolinska University Hospital. Pneumococcal vaccine in untreated CLL patients; 2013"},{"key":"10.1016\/j.vaccine.2021.03.079_b1360","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/jama.2014.14825","article-title":"Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes","volume":"312","author":"Kharbanda","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.03.079_b1365","unstructured":"Korea University Guro Hospital. Influenza Vaccine and Pneumococcal Vaccine. https:\/\/ClinicalTrials.gov\/show\/NCT02582047; 2012."},{"key":"10.1016\/j.vaccine.2021.03.079_b1370","unstructured":"Korea University Guro Hospital. Immunogenicity and safety of a tetanus-diphtheria vaccine and a 13-valent pneumococcal conjugate vaccine; 2013."},{"key":"10.1016\/j.vaccine.2021.03.079_b1375","unstructured":"Korea University Guro Hospital, Novartis. MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine; 2013"},{"key":"10.1016\/j.vaccine.2021.03.079_b1380","unstructured":"Korea University Guro Hospital, Pfizer. Immunogenicity and safety of PCV13 and fluad in adults aged \u226560 years; 2014."},{"key":"10.1016\/j.vaccine.2021.03.079_b1385","unstructured":"Laval University. Immunogenicity and safety of gardasil-9 and cervarix; 2015"},{"key":"10.1016\/j.vaccine.2021.03.079_b1390","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/21645515.2015.1085143","article-title":"Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants","volume":"12","author":"Li","year":"2016","journal-title":"Hum Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b1395","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.4161\/hv.25076","article-title":"Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled Phase I studies","volume":"9","author":"Li","year":"2013","journal-title":"Hum Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b1400","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.vaccine.2019.03.043","article-title":"Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials","volume":"37","author":"Lopez-Fauqued","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b1405","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/21645515.2015.1012010","article-title":"Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine","volume":"11","author":"Luxembourg","year":"2015","journal-title":"Hum Vaccines and Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b1410","first-page":"E270","article-title":"End of study efficacy, immunogenicity and safety of a novel 9-valent HPV l1 virus-like particle vaccine in 16\u201326 year old women","volume":"131","author":"Mayrand","year":"2015","journal-title":"Int J Gynecology Obstetrics (varpagings)"},{"key":"10.1016\/j.vaccine.2021.03.079_b1415","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw194.40","article-title":"Efficacy, immunogenicity and safety of an investigational subunit adjuvanted herpes zoster vaccine in adults aged 60 years and older: results from the zoe-50 and zoe-70 efficacy studies","volume":"3","author":"McElhaney","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b1420","unstructured":"MedImmune LLC. A study to evaluate the immunogenicity of quadrivalent LAIV in Adults 18 to 49 Years of Age. https:\/\/ClinicalTrials.gov\/show\/NCT00860067; 2009."},{"key":"10.1016\/j.vaccine.2021.03.079_b1425","unstructured":"MedImmune LLC. A study to evaluate the immunogenicity of quadrivalent live attenuated influenza vaccine (LAIV) in children. https:\/\/ClinicalTrials.gov\/show\/NCT01091246; 2010."},{"key":"10.1016\/j.vaccine.2021.03.079_b1430","unstructured":"MedImmune LLC. Postmarketing safety study of Q\/LAIV in subjects 2 through 49 years of age. https:\/\/ClinicalTrials.gov\/show\/NCT01985997; 2014."},{"key":"10.1016\/j.vaccine.2021.03.079_b1435","unstructured":"MedImmune LLC, AstraZeneca. Evaluate the shedding and immunogencity of different formulations of FluMist in children 24 to <48 months of age; 2017."},{"key":"10.1016\/j.vaccine.2021.03.079_b1440","unstructured":"Merck Sharp, Dohme Corp. Efficacy, safety, and immunogenicity of V260 in healthy chinese infants (V260-024); 2015."},{"key":"10.1016\/j.vaccine.2021.03.079_b1445","unstructured":"Merck Sharp, Dohme Corp. Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068); 2006."},{"key":"10.1016\/j.vaccine.2021.03.079_b1450","unstructured":"Merck Sharp, Dohme Corp. Broad spectrum HPV (human papillomavirus) vaccine study in 16-to 26-year-old women (V503-001); 2007."},{"key":"10.1016\/j.vaccine.2021.03.079_b1455","unstructured":"Merck Sharp, Dohme Corp. Immunogenicity and safety study of proquad\u00ae and infanrix\u00ae hexa when administered concomitantly (V221-035); 2007."},{"key":"10.1016\/j.vaccine.2021.03.079_b1460","unstructured":"Merck Sharp, Dohme Corp. Phase III Placebo-controlled Study of V260 (RotaTeq\u2122) in Japanese Healthy Infants (V260-029)(COMPLETED). https:\/\/ClinicalTrials.gov\/show\/NCT00718237; 2008."},{"key":"10.1016\/j.vaccine.2021.03.079_b1465","unstructured":"Merck Sharp, Dohme Corp. A Study of V503, a 9-valent human papillomavirus (9vHPV) vaccine in females 12-26 years of age who have previously received GARDASIL\u2122 (V503-006); 2010."},{"key":"10.1016\/j.vaccine.2021.03.079_b1470","unstructured":"Merck Sharp, Dohme Corp. Immunogenicity and tolerability of V503 versus GARDASIL (V503-009); 2011."},{"key":"10.1016\/j.vaccine.2021.03.079_b1475","unstructured":"Merck Sharp, Dohme Corp. A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020). 2014."},{"key":"10.1016\/j.vaccine.2021.03.079_b1480","unstructured":"Merck Sharp, Dohme Corp., MCM vaccines B.V. A study of V419 given concomitantly with prevnar 13\u2122 and RotaTeq\u2122 (V419-006); 2011."},{"key":"10.1016\/j.vaccine.2021.03.079_b1485","unstructured":"Merck Sharp, Dohme Corp., MCM Vaccines B.V. Safety, tolerability, and immunogenicity of V419 given concomitantly with prevnar 13\u2122 and RotaTeq\u2122 (V419-005); 2011."},{"key":"10.1016\/j.vaccine.2021.03.079_b1490","doi-asserted-by":"crossref","unstructured":"Munoz FM, Bond NH, Maccato M. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial (vol 311, pg 1760, 2014). Jama-J Am Med Assoc 2017;317:442-.","DOI":"10.1001\/jama.2014.3633"},{"key":"10.1016\/j.vaccine.2021.03.079_b1495","unstructured":"National Institute of Allergy Infectious Diseases. Pertussis vaccine in healthy pregnant women; 2009"},{"key":"10.1016\/j.vaccine.2021.03.079_b1500","unstructured":"Novartis, novartis vaccines. Study to evaluate the safety of novartis MenACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants; 2008"},{"key":"10.1016\/j.vaccine.2021.03.079_b1505","unstructured":"Novartis, novartis vaccines. A phase 3b, randomized, open-label study to evaluate the safety and immunogenicity of select travel vaccines when administered concomitantly with MenACWY in adults; 2011"},{"key":"10.1016\/j.vaccine.2021.03.079_b1510","unstructured":"Novartis, novartis vaccines. A phase 4, placebo-controlled, randomized study to evaluate the immunogenicity and safety of HPV and tdap when administered with MenACWY in adolescents; 2011"},{"key":"10.1016\/j.vaccine.2021.03.079_b1515","unstructured":"Novartis vaccines, glaxosmithkline, novartis. Study to evaluate the safety and immunogenicity of combined hepatitis A\/B vaccine with MenACWY-CRM conjugate vaccine; 2011"},{"key":"10.1016\/j.vaccine.2021.03.079_b1520","unstructured":"Novartis vaccines, novartis. Safety and immunogenicity of meningococcal ACWY conjugate versus polysaccharide vaccine in children 2 to 10 years of age; 2006."},{"key":"10.1016\/j.vaccine.2021.03.079_b1525","doi-asserted-by":"crossref","unstructured":"Novartis vaccines, novartis. A study to evaluate safety and immune response of novartis meningococcal ACWY vaccine in infants; 2007","DOI":"10.3833\/pdr.v2007i86.302"},{"key":"10.1016\/j.vaccine.2021.03.079_b1530","unstructured":"Novartis vaccines, novartis. Safety, tolerability and immunogenicity of novartis meningococcal B recombinant vaccine administered to healthy adolescents according to different vaccination schedules; 2008"},{"key":"10.1016\/j.vaccine.2021.03.079_b1535","unstructured":"Novartis vaccines, novartis. A multi-center, observer-blind, placebo-controlled, randomized study to evaluate the immunogenicity and safety of MenACWY in adolescents and adults in Korea; 2010"},{"key":"10.1016\/j.vaccine.2021.03.079_b1540","unstructured":"Novartis vaccines, novartis. Safety and Immunogenicity of MF59C.1 adjuvanted trivalent subunit influenza vaccine in elderly subjects; 2010"},{"key":"10.1016\/j.vaccine.2021.03.079_b1545","unstructured":"Novartis vaccines, novartis. Safety and immunogenicity of three influenza vaccines adults ages 18 and older; 2014."},{"key":"10.1016\/j.vaccine.2021.03.079_b1550","unstructured":"Novartis vaccines, novartis. Safety and immunogenicity of three influenza vaccines in children aged 4 years old to less than 18 years old; 2014"},{"key":"10.1016\/j.vaccine.2021.03.079_b1555","unstructured":"Novartis vaccines, novartis. Safety and immunogenicity study of two doses of novartis meningococcal serogroup B recombinant vaccine in adolescents aged 11-17 years; 2014"},{"key":"10.1016\/j.vaccine.2021.03.079_b1560","unstructured":"Novartis vaccines and diagnostics S.r.l. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants; 2014."},{"key":"10.1016\/j.vaccine.2021.03.079_b1565","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1080\/21645515.2019.1627818","article-title":"Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials","volume":"15","author":"Oostvogels","year":"2019","journal-title":"Hum Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b1570","first-page":"173","article-title":"Pertussis vaccination during pregnancy: a multicountry randomised placebo-controlled trial assessing immunogenicity and safety of dTpa in mothers and their infants","volume":"126","author":"Perrett","year":"2019","journal-title":"BJOG"},{"key":"10.1016\/j.vaccine.2021.03.079_b1575","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.vaccine.2019.10.104","article-title":"Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial","volume":"38","author":"Perrett","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b1580","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pvr.2017.03.002","article-title":"Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine \u2013 A combined analysis of five phase III clinical trials","volume":"3","author":"Petersen","year":"2017","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.vaccine.2021.03.079_b1585","article-title":"Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (menacyw-TT) administered in adults 18\u201355 years of age","author":"Peterson","year":"20196957","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b1590","article-title":"Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (menacyw-TT) administered in adolescents 10\u201317 years of age","author":"Peterson","year":"20196958","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b1595","article-title":"Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on","author":"Pfizer","year":"2007","journal-title":"Nasopharyngeal Colonization"},{"key":"10.1016\/j.vaccine.2021.03.079_b1600","unstructured":"Pfizer. Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine. https:\/\/ClinicalTrials.gov\/show\/NCT00521586; 2007."},{"key":"10.1016\/j.vaccine.2021.03.079_b1605","unstructured":"Pfizer. Study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine with influenza vaccine in adults. https:\/\/ClinicalTrials.gov\/show\/NCT00492557; 2007."},{"key":"10.1016\/j.vaccine.2021.03.079_b1610","unstructured":"Pfizer. Study evaluating the effiacy of a 13-valent pneumococcal conjugate vaccine (13vPnC) in adults; 2008"},{"key":"10.1016\/j.vaccine.2021.03.079_b1615","unstructured":"Pfizer. A study evaluating safety and immunogenicity of meningococcal B Rlp2086 vaccine in adolescents; 2009"},{"key":"10.1016\/j.vaccine.2021.03.079_b1620","unstructured":"Pfizer. Trial evaluating a 13-valent pneumococcal conjugate vaccine given with diphtheria, tetanus, and acellular pertussis vaccine (DTaP) in Healthy Japanese Infants; 2010"},{"key":"10.1016\/j.vaccine.2021.03.079_b1625","unstructured":"Pfizer. A trial to assess the safety, tolerability and immunogenicity of repevax and rLP2086 vaccine when given together in healthy subjects aged >=11 to <19 years; 2011."},{"key":"10.1016\/j.vaccine.2021.03.079_b1630","unstructured":"Pfizer. A global phase 3 safety study of 120 mcg rLP2086 vaccine in adolescents and young adults aged 10 to 25 years; 2012."},{"key":"10.1016\/j.vaccine.2021.03.079_b1635","unstructured":"Pfizer. Immunogenicity and safety study of 1 and 2 doses of GlaxoSmithKline (GSK) biologicals' meningococcal vaccine MenACWY-TT (GSK134612) in toddlers, persistence up to 5 years after vaccination and co-administration with pfizer's prevenar 13\u2122 vaccine; 2013."},{"key":"10.1016\/j.vaccine.2021.03.079_b1640","article-title":"Concomitant administration of 13-valent pneumococcal conjugate vaccine (13vPnC) with influenza vaccine in 23-valent pneumococcal polysaccharide (23vPS)","author":"Pfizer","year":"2015","journal-title":"Pre-vaccinated Adults"},{"key":"10.1016\/j.vaccine.2021.03.079_b1645","unstructured":"Pfizer Winawoso. Study evaluating a 13-valent pneumococcal conjugate vaccine administered to infants In Korea. https:\/\/ClinicalTrials.gov\/show\/NCT00689351; 2008."},{"key":"10.1016\/j.vaccine.2021.03.079_b1650","unstructured":"Protein Sciences Corporation. Protective efficacy of Flublok\u00ae quadrivalent versus licensed inactivated influenza vaccine in adults \u226550 years of age; 2015"},{"key":"10.1016\/j.vaccine.2021.03.079_b1655","unstructured":"Protein sciences corporation, syneos health, department of health human services. Safety and immunogenicity of flublok quadrivalent vs IIV4 in adults 18-49 years of age; 2015"},{"key":"10.1016\/j.vaccine.2021.03.079_b1660","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamapediatrics.2013.2745","article-title":"Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children","volume":"167","author":"Rowhani-Rahbar","year":"2013","journal-title":"JAMA Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b1665","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pvr.2017.12.004","article-title":"Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women","volume":"5","author":"Ruiz-Sternberg","year":"2018","journal-title":"Papillomavirus Res (Amsterdam, Netherlands)"},{"key":"10.1016\/j.vaccine.2021.03.079_b1670","unstructured":"Sanofi Pasteur a Sanofi Company. Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine."},{"key":"10.1016\/j.vaccine.2021.03.079_b1675","unstructured":"Sanofi Pasteur a Sanofi Company, Merck Sharp, Dohme Corp., Sanofi. Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar\u00ae; 2006"},{"key":"10.1016\/j.vaccine.2021.03.079_b1680","unstructured":"Sanofi Pasteur a Sanofi Company, Sanofi. 36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds; 2005."},{"key":"10.1016\/j.vaccine.2021.03.079_b1685","unstructured":"Sanofi Pasteur a Sanofi Company, Sanofi. Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine; 2005"},{"key":"10.1016\/j.vaccine.2021.03.079_b1690","unstructured":"Sanofi Pasteur a Sanofi Company, Sanofi. Database Surveillance Safety Study of PENTACEL\u00ae Vaccine; 2008"},{"key":"10.1016\/j.vaccine.2021.03.079_b1695","unstructured":"Sanofi Pasteur a Sanofi Company, Sanofi. A study of influenza virus vaccines in children and adults; 2009"},{"key":"10.1016\/j.vaccine.2021.03.079_b1700","unstructured":"Sanofi Pasteur a Sanofi Company, Sanofi. Study of quadrivalent influenza vaccine among children; 2010"},{"key":"10.1016\/j.vaccine.2021.03.079_b1705","unstructured":"Sanofi Pasteur a Sanofi Company, Sanofi. Study of Quadrivalent Influenza Vaccine Among Adults. https:\/\/ClinicalTrials.gov\/show\/NCT01218646; 2010."},{"key":"10.1016\/j.vaccine.2021.03.079_b1710","unstructured":"Sanofi Pasteur a Sanofi Company, Sanofi. Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children; 2011"},{"key":"10.1016\/j.vaccine.2021.03.079_b1715","unstructured":"Sanofi Pasteur a Sanofi Company, Sanofi. Safety and immunogenicity in adults of revaccination with Adacel\u00ae vaccine 10 years after a previous dose; 2011"},{"key":"10.1016\/j.vaccine.2021.03.079_b1720","unstructured":"Sanofi Pasteur a Sanofi Company, Sanofi. Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine in healthy adolescents; 2014"},{"key":"10.1016\/j.vaccine.2021.03.079_b1725","unstructured":"Sanofi Pasteur a Sanofi Company, Sanofi. Immunogenicity and safety of a booster dose of an investigational quadrivalent meningococcal conjugate vaccine; 2016"},{"key":"10.1016\/j.vaccine.2021.03.079_b1730","unstructured":"Sanofi Pasteur a Sanofi Company, Sanofi. Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine in adults 56 years and older; 2016"},{"key":"10.1016\/j.vaccine.2021.03.079_b1735","unstructured":"Sanofi Pasteur a Sanofi Company, Sanofi. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in participants \u226565 years in the US; 2017"},{"key":"10.1016\/j.vaccine.2021.03.079_b1740","unstructured":"Sanofi Pasteur aSC, Sanofi. study of a quadrivalent meningococcal conjugate vaccine in subjects aged 56 and older. https:\/\/ClinicalTrials.gov\/show\/NCT01732627; 2012."},{"key":"10.1016\/j.vaccine.2021.03.079_b1745","unstructured":"Sanofi Pasteur aSC, Sanofi. Study of an investigational quadrivalent meningococcal conjugate vaccine administered in children aged 2 to 9 years. https:\/\/ClinicalTrials.gov\/show\/NCT03077438; 2017."},{"key":"10.1016\/j.vaccine.2021.03.079_b1750","series-title":"IWK Health Centre, Sanofi Pasteur a Sanofi Company","author":"Halperin","year":"2007"},{"key":"10.1016\/j.vaccine.2021.03.079_b1755","unstructured":"Scott J. Statistical analysis of heplisav-B AMI risk. Vaccines and related biological products advisory committee meeting: U.S. food & drug administration; July 28, 2017."},{"key":"10.1016\/j.vaccine.2021.03.079_b1760","unstructured":"Seqirus. Phase 3 safety and immunogenicity study of aQIV in elderly adults."},{"key":"10.1016\/j.vaccine.2021.03.079_b1765","unstructured":"Seqirus. A study to evaluate the immunogenicity and safety of bioCSL quadrivalent influenza vaccine (QIV) in adults aged 18 years and above; 2014."},{"key":"10.1016\/j.vaccine.2021.03.079_b1770","doi-asserted-by":"crossref","first-page":"S958","DOI":"10.1093\/ofid\/ofz360.2401","article-title":"Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (menacyw-TT) administered in healthy meningococcal vaccine-na\u00c3\u00afve children (2\u20139 years)","volume":"6","author":"Simon","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b1775","unstructured":"Statens Serum Institut. Pneumococcal vaccination of Crohn patients - A randomized, non-blinded phase 4 clinical trial with the purpose of investigating the immune response against two different pneumococcal vaccines in patients with Crohn's disease; 2013."},{"key":"10.1016\/j.vaccine.2021.03.079_b1780","series-title":"Hvidovre University Hospital","author":"Statens Serum Institut","year":"2013"},{"key":"10.1016\/j.vaccine.2021.03.079_b1785","unstructured":"The University of Hong Kong, Centers for disease control prevention. Immunogenicity of alternative annual influenza vaccination strategies in older adults in Hong Kong; 2017."},{"key":"10.1016\/j.vaccine.2021.03.079_b1790","unstructured":"U.S Food and Drug Administration. Clinical Review, November 9, 2017-Heplisav-B: BLA Clinical Review Memorandum; 2017."},{"key":"10.1016\/j.vaccine.2021.03.079_b1795","unstructured":"University D, Centers for disease control prevention, kaiser permanente. Fever after simultaneous versus sequential vaccination in young children; 2018."},{"key":"10.1016\/j.vaccine.2021.03.079_b1800","unstructured":"University of Newcastle, National Health and Medical Research Council. Pneumococcal polysaccharide vaccine versus Normal Saline for primary prevention of heart attacks and strokes in at-risk Australians aged 55-60; 2015."},{"key":"10.1016\/j.vaccine.2021.03.079_b1805","unstructured":"University of Siena, Ministry of education universities, research Italy. Serological response to antipneumococcal vaccination and impact on streptococcus pneumoniae nasal carriage in HIV Adults; 2011"},{"key":"10.1016\/j.vaccine.2021.03.079_b1810","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2217\/fmb.15.80","article-title":"The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?","volume":"10","author":"van Werkhoven","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2021.03.079_b1815","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.12.047","article-title":"Evaluating clinical effectiveness of pneumococcal vaccination in preventing stroke: the CAPAMIS Study, 3-year follow-up","volume":"23","author":"Vila-Corcoles","year":"2014","journal-title":"J Stroke Cerebrovascular Dis: Official J National Stroke Assoc"},{"key":"10.1016\/j.vaccine.2021.03.079_b1820","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/1471-2458-12-222","article-title":"Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up","volume":"12","author":"Vila-Corcoles","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2021.03.079_b1825","unstructured":"Wyeth is now a wholly owned subsidiary of Pfizer. Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects. https:\/\/ClinicalTrials.gov\/show\/NCT00269672; 2005."},{"key":"10.1016\/j.vaccine.2021.03.079_b1830","unstructured":"Wyeth is now a wholly owned subsidiary of Pfizer. Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS. https:\/\/ClinicalTrials.gov\/show\/NCT00574548; 2007."},{"key":"10.1016\/j.vaccine.2021.03.079_b1835","doi-asserted-by":"crossref","unstructured":"Yih K, Lieu T, Kulldorff M, Martin D, McMahill-Walraven C, Platt R, et al. Intussusception Risk After Rotavirus Vaccination in U.S. Infants. Available at: http:\/\/www.mini-sentinel.org\/work_products\/PRISM\/Mini-Sentinel_PRISM_Rotavirus-and-intussusception-Report.pdf. Mini-Sentinel Coordinating Center; June 2013.","DOI":"10.1056\/NEJMoa1303164"},{"key":"10.1016\/j.vaccine.2021.03.079_b1840","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.vaccine.2011.06.009","article-title":"A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark","volume":"30","author":"Andrews","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b1845","doi-asserted-by":"crossref","first-page":"7215","DOI":"10.1016\/j.vaccine.2010.08.062","article-title":"Post-licensure comparison of the safety profile of diphtheria\/tetanus\/whole cell pertussis\/haemophilus influenza type b vaccine and a 5-in-1 diphtheria\/tetanus\/acellular pertussis\/haemophilus influenza type b\/polio vaccine in the United Kingdom","volume":"28","author":"Andrews","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b1850","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(10)60889-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Armah","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.03.079_b1855","first-page":"791","article-title":"Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus","volume":"30","author":"Barbosa","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.vaccine.2021.03.079_b1860","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0140-6736(10)62228-3","article-title":"Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"377","author":"Barrett","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.03.079_b1865","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/cit222","article-title":"Lack of association of guillain-barre syndrome with vaccinations","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b1870","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.vaccine.2012.02.080","article-title":"A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18\u201349 years of age","volume":"30","author":"Baxter","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b1875","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/j.vaccine.2012.02.039","article-title":"A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age","volume":"30","author":"Baxter","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b1880","doi-asserted-by":"crossref","first-page":"6636","DOI":"10.1016\/j.vaccine.2012.08.070","article-title":"Safety of ZostavaxTM\u2013a cohort study in a managed care organization","volume":"30","author":"Baxter","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b1885","doi-asserted-by":"crossref","first-page":"e1811","DOI":"10.1542\/peds.2012-3567","article-title":"Safety and utilization of influenza immunization in children with inflammatory bowel disease","volume":"131","author":"Benchimol","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b1890","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.vaccine.2005.10.056","article-title":"Diphtheria tetanus pertussis poliomyelitis vaccination and reported atopic disorders in 8\u201312-year-old children","volume":"24","author":"Bernsen","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b1895","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11530350-000000000-00000","article-title":"Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy","volume":"33","author":"Bertuola","year":"2010","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2021.03.079_b1900","doi-asserted-by":"crossref","unstructured":"Bhatla N, Suri V, Basu P, Shastri S, Datta SK, Bi D, et al. Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.[Erratum appears in J Obstet Gynaecol Res. 2010 Apr;36(2):466]. J Obstet Gynaecol Res. 2010;36:123-32","DOI":"10.1111\/j.1447-0756.2009.01167.x"},{"key":"10.1016\/j.vaccine.2021.03.079_b1905","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/INF.0b013e3181b77906","article-title":"Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (Types 6, 11, 16, and 18) L1 virus-like particle vaccine","volume":"29","author":"Block","year":"2010","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b1910","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1542\/peds.2006-2058","article-title":"Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life","volume":"119","author":"Block","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b1915","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1016\/j.vaccine.2011.01.088","article-title":"Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia","volume":"29","author":"Buttery","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b1920","doi-asserted-by":"crossref","first-page":"516","DOI":"10.4269\/ajtmh.1996.55.516","article-title":"The immunogenicity of three Haemophilus influenzae type B conjugate vaccines after a primary vaccination series in Philippine infants","volume":"55","author":"Capeding","year":"1996","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2021.03.079_b1925","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0929-6646(09)60067-X","article-title":"Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan","volume":"108","author":"Chang","year":"2009","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.vaccine.2021.03.079_b1930","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2796.2011.02467.x","article-title":"Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine","volume":"271","author":"Chao","year":"2012","journal-title":"J Intern Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b1935","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1542\/peds.99.6.765","article-title":"Vaccine safety datalink project: A new tool for improving vaccine safety monitoring in the United States","volume":"99","author":"Chen","year":"1997","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b1940","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jadohealth.2012.07.003","article-title":"Clinical trial experience with prophylactic human papillomavirus 6\/11\/16\/18 vaccine in young black women","volume":"52","author":"Clark","year":"2013","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2021.03.079_b1945","doi-asserted-by":"crossref","first-page":"574","DOI":"10.5694\/mja12.10534","article-title":"Guillain-Barre syndrome following pandemic (H1N1) 2009 influenza A immunisation in Victoria: a self-controlled case series","volume":"197","author":"Crawford","year":"2012","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2021.03.079_b1950","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1016\/j.vaccine.2010.07.007","article-title":"Sustained efficacy and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women","volume":"28","author":"De Carvalho","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b1955","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/01.inf.0000164763.55558.71","article-title":"Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine","volume":"24","author":"Dennehy","year":"2005","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b1960","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S1701-2163(16)35336-1","article-title":"The association between influenza vaccine in pregnancy and adverse neonatal outcomes","volume":"34","author":"Dodds","year":"2012","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.vaccine.2021.03.079_b1965","doi-asserted-by":"crossref","unstructured":"Duderstadt SK, Rose CE, Jr., Real TM, Sabatier JF, Stewart B, Ma G, et al. Vaccination and risk of type 1 diabetes mellitus in active component U.S. Military, 2002-2008. Vaccine. 2012;30:813-9.","DOI":"10.1016\/j.vaccine.2011.10.087"},{"key":"10.1016\/j.vaccine.2021.03.079_b1970","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/acr.20496","article-title":"Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis","volume":"63","author":"Eder","year":"2011","journal-title":"Arthritis Care and Res"},{"key":"10.1016\/j.vaccine.2021.03.079_b1975","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/INF.0b013e3181b84c34","article-title":"Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study","volume":"29","author":"Englund","year":"2010","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b1980","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/heartjnl-2012-301743","article-title":"Pneumococcal vaccination and risk of acute coronary syndromes in patients with pneumonia: population-based cohort study","volume":"98","author":"Eurich","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.vaccine.2021.03.079_b1985","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/1352458511417253","article-title":"H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study","volume":"18","author":"Farez","year":"2012","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.vaccine.2021.03.079_b1990","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.2105\/AJPH.2011.300606","article-title":"H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes","volume":"102","author":"Fell","year":"2012","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2021.03.079_b1995","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1086\/656578","article-title":"Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults","volume":"51","author":"Frey","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b2000","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1080\/15287394.2010.519317","article-title":"Hepatitis B vaccination of male neonates and autism diagnosis, NHIS 1997\u20132002","volume":"73","author":"Gallagher","year":"2010","journal-title":"J Toxicol Environ Health-Part a-Curr Issues"},{"key":"10.1016\/j.vaccine.2021.03.079_b2005","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00228-011-1184-3","article-title":"Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study","volume":"68","author":"Garbe","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2010","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1016\/j.vaccine.2011.08.106","article-title":"Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink","volume":"29","author":"Gee","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2015","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1093\/ndt\/gfq853","article-title":"The association of pneumococcal vaccination with hospitalization and mortality in hemodialysis patients","volume":"26","author":"Gilbertson","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.vaccine.2021.03.079_b2020","doi-asserted-by":"crossref","unstructured":"Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Jr., Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.[Erratum appears in N Engl J Med. 2011 Apr 14;364(15):1481]. New Engl J Med 2011;364:401-11","DOI":"10.1056\/NEJMoa0909537"},{"key":"10.1016\/j.vaccine.2021.03.079_b2025","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/archpediatrics.2011.112","article-title":"Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink","volume":"165","author":"Glanz","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b2030","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1016\/j.vaccine.2010.04.021","article-title":"Use of the Australian Childhood Immunisation Register for vaccine safety data linkage","volume":"28","author":"Gold","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2035","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1399-3046.2010.01420.x","article-title":"Effectiveness and safety of inactivated influenza vaccination in pediatric liver transplant recipients over three influenza seasons","volume":"15","author":"Gotoh","year":"2011","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.vaccine.2021.03.079_b2040","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/aje\/kws195","article-title":"Risk of confirmed guillain-barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the vaccine safety datalink project, 2009\u20132010","volume":"175","author":"Greene","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2045","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.anai.2012.09.011","article-title":"Safe administration of the seasonal trivalent influenza vaccine to children with severe egg allergy","volume":"109","author":"Greenhawt","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2050","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/aje\/kwr072","article-title":"Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A\/H1N1 viruses","volume":"174","author":"Grimaldi-Bensouda","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2055","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bjc.6690668","article-title":"Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA","volume":"81","author":"Groves","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2021.03.079_b2060","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/j.1398-9995.2008.01696.x","article-title":"Early atopic disease and early childhood immunization\u2013is there a link?","volume":"63","author":"Gruber C, Warner J, Hill D, Bauchau V, Group ES","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.vaccine.2021.03.079_b2065","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.vaccine.2010.12.017","article-title":"The effect of influenza vaccination on risk of acute myocardial infarction: self-controlled case-series study","volume":"29","author":"Gwini","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2070","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1016\/j.vaccine.2011.03.097","article-title":"Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer","volume":"29","author":"Halasa","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2075","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1542\/peds.2011-1294","article-title":"Trivalent inactivated influenza vaccine is not associated with sickle cell crises in children","volume":"129","author":"Hambidge","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b2080","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.1016\/j.vaccine.2011.09.002","article-title":"team VSD. Trivalent inactivated influenza vaccine is not associated with sickle cell hospitalizations in adults from a large cohort","volume":"29","author":"Hambidge","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2085","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1016\/S0264-410X(03)00296-2","article-title":"Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: A 1-year follow-up","volume":"21","author":"Hedlund","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2090","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2337\/diacare.23.7.969","article-title":"No major association of breast-feeding, vaccinations, and childhood viral diseases with early islet autoimmunity in the German BABYDIAB study","volume":"23","author":"Hummel","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.vaccine.2021.03.079_b2095","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2215\/CJN.05430610","article-title":"Outcomes associated with influenza vaccination in the first year after kidney transplantation","volume":"6","author":"Hurst","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-2334-13-95","article-title":"Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial","volume":"13","author":"Huu","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b2105","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archinternmed.2010.49","article-title":"Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study","volume":"170","author":"Iorio","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b2110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/AOG.0b013e318279f56f","article-title":"Trivalent inactivated influenza vaccine and spontaneous abortion","volume":"121","author":"Irving","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2115","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.1016\/j.vaccine.2012.09.032","article-title":"Autoimmune disorders after immunisation with Influenza A\/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review","volume":"30","author":"Isai","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2120","doi-asserted-by":"crossref","unstructured":"Italian Multicenter Study Group for D, Vaccine Safety in C. Effectiveness and safety of the A-H1N1 vaccine in children: a hospital-based case-control study. BMJ Open. 2011;1:e000167.","DOI":"10.1136\/bmjopen-2011-000167"},{"key":"10.1016\/j.vaccine.2021.03.079_b2125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2334-10-71","article-title":"Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons","volume":"10","author":"Jackson","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b2130","article-title":"Influenza vaccination and major adverse vascular events in high risk patients","volume":"21","author":"Johnstone","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2021.03.079_b2135","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1525-1438.2007.01123.x","article-title":"Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects","volume":"18","author":"Kang","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.vaccine.2021.03.079_b2140","doi-asserted-by":"crossref","first-page":"6335","DOI":"10.1016\/j.vaccine.2011.05.017","article-title":"Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life","volume":"29","author":"Kawamura","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2145","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/INF.0b013e31825686d0","article-title":"The vaccine-attributable risk for febrile convulsions following influenza vaccine","volume":"31","author":"Kelly","year":"2012","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b2150","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4161\/hv.6.3.10428","article-title":"Immunogenicity of a live-attenuated human rotavirus RIX4414 vaccine with or without buffering agent","volume":"6","author":"Kerdpanich","year":"2010","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2021.03.079_b2155","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1128\/CVI.00260-12","article-title":"Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine","volume":"19","author":"Khalil","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/jjco\/hyr173","article-title":"Safety and immunogenicity profile of human papillomavirus-16\/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh","volume":"42","author":"Khatun","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2165","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/INF.0b013e31815aba79","article-title":"Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea","volume":"27","author":"Kim","year":"2008","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b2170","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4161\/hv.19853","article-title":"Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: A randomized, double-blind, placebo-controlled, phase IV study","volume":"8","author":"Kim","year":"2012","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b2175","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3802\/jgo.2011.22.2.67","article-title":"Human papillomavirus 16\/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15\u201325 years old healthy Korean women","volume":"22","author":"Kim","year":"2011","journal-title":"J Gynecologic Oncology"},{"key":"10.1016\/j.vaccine.2021.03.079_b2180","doi-asserted-by":"crossref","first-page":"e1139","DOI":"10.1542\/peds.2010-3706","article-title":"Evaluation of immunization rates and safety among children with inborn errors of metabolism","volume":"127","author":"Klein","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b2185","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archpediatrics.2012.1451","article-title":"Safety of quadrivalent human papillomavirus vaccine administered routinely to females","volume":"166","author":"Klein","year":"2012","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b2190","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1542\/peds.2007-1462","article-title":"Risk factors for developing apnea after immunization in the neonatal intensive care unit","volume":"121","author":"Klein","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b2195","doi-asserted-by":"crossref","unstructured":"Klein NP, Reisinger KS, Johnston W, Odrljin T, Gill CJ, Bedell L, et al. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.[Erratum appears in Pediatr Infect Dis J. 2012 Oct;31(10):1105]. Pediatric Infectious Disease Journal. 2012;31:64-71","DOI":"10.1097\/INF.0b013e31823dce5c"},{"key":"10.1016\/j.vaccine.2021.03.079_b2200","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.vaccine.2010.12.100","article-title":"A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness","volume":"29","author":"Langley","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2205","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amepre.2011.04.004","article-title":"H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project","volume":"41","author":"Lee","year":"2011","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b2210","doi-asserted-by":"crossref","first-page":"7638","DOI":"10.1016\/j.vaccine.2011.08.003","article-title":"Immunogenicity and safety of a single intramuscular dose of a diphtheria-tetanus toxoid (Td) vaccine (GC1107) in Korean adults","volume":"29","author":"Lee","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2215","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e3181de8d26","article-title":"Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old","volume":"55","author":"Levin","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.vaccine.2021.03.079_b2220","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1016\/j.vaccine.2012.02.079","article-title":"Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females","volume":"30","author":"Li","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2225","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1016\/j.vaccine.2012.02.008","article-title":"AdimFlu-S((registered trademark)) influenza A (H1N1) vaccine during pregnancy: The Taiwanese Pharmacovigilance Survey","volume":"30","author":"Lin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2230","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/ije\/dyi113","article-title":"Vaccination history and risk of childhood leukaemia","volume":"34","author":"Ma","year":"2005","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2235","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.vaccine.2006.11.011","article-title":"Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults","volume":"25","author":"Macaladad","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2240","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/aje\/kwm339","article-title":"Risk of childhood leukemia associated with vaccination, infection, and medication use in childhood: the Cross-Canada Childhood Leukemia Study","volume":"167","author":"MacArthur","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2245","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJMoa0904797","article-title":"Effect of human rotavirus vaccine on severe diarrhea in African infants","volume":"362","author":"Madhi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b2250","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/QAD.0b013e32835ab5b2","article-title":"Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial","volume":"27","author":"Madhi","year":"2013","journal-title":"Aids"},{"key":"10.1016\/j.vaccine.2021.03.079_b2255","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/cid\/ciq004","article-title":"Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety","volume":"52","author":"Madhi","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b2260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013755","article-title":"Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials","volume":"5","author":"Mallory","year":"2010","journal-title":"PLoS ONE [Electronic Resource]"},{"key":"10.1016\/j.vaccine.2021.03.079_b2265","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1399-3038.2009.00950.x","article-title":"Childhood immunization and atopic disease into middle-age\u2013a prospective cohort study","volume":"21","author":"Matheson","year":"2010","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2270","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1016\/j.vaccine.2010.04.003","article-title":"Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster","volume":"28","author":"Mills","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2275","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ppul.20089","article-title":"Infant immunization and the occurrence of atopic disease in Dutch and German children: a nested case-control study","volume":"38","author":"Mommers","year":"2004","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2280","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4161\/hv.7.7.15579","article-title":"Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults","volume":"7","author":"Moreira","year":"2011","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2021.03.079_b2285","doi-asserted-by":"crossref","first-page":"e1147","DOI":"10.1542\/peds.2010-1628","article-title":"Vaccines are not associated with metabolic events in children with urea cycle disorders","volume":"127","author":"Morgan","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b2290","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/pds.1272","article-title":"Vaccines, antibiotics, and atopy","volume":"16","author":"Mullooly","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2021.03.079_b2295","doi-asserted-by":"crossref","first-page":"7611","DOI":"10.1016\/j.vaccine.2011.08.022","article-title":"team VSD. Wheezing lower respiratory disease and vaccination of premature infants","volume":"29","author":"Mullooly","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2300","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4161\/hv.7.11.17982","article-title":"Safety and tolerability of zoster vaccine in adults >=60 years old","volume":"7","author":"Murray","year":"2011","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2021.03.079_b2305","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/thx.2006.062547","article-title":"Is childhood immunisation associated with atopic disease from age 7 to 32 years?","volume":"62","author":"Nakajima","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.vaccine.2021.03.079_b2310","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4161\/hv.5.6.8176","article-title":"Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants","volume":"5","author":"Narang","year":"2009","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2021.03.079_b2315","first-page":"171","article-title":"Human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine: Immunogenicity and safety in healthy Chinese women from Hong Kong","volume":"16","author":"Ngan","year":"2010","journal-title":"Hong Kong Medical J"},{"key":"10.1016\/j.vaccine.2021.03.079_b2320","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/AOG.0b013e3182831b83","article-title":"Maternal safety of trivalent inactivated influenza vaccine in pregnant women","volume":"121","author":"Nordin","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2325","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1542\/peds.2011-1111","article-title":"The risk of immune thrombocytopenic purpura after vaccination in children and adolescents","volume":"129","author":"O'Leary","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b2330","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/INF.0b013e3182490a2c","article-title":"Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study","volume":"31","author":"Omenaca","year":"2012","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b2335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000441","article-title":"Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study","volume":"8","author":"Omer","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b2340","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jpeds.2010.11.054","article-title":"Associations between vaccination and childhood cancers in Texas regions","volume":"158","author":"Pagaoa","year":"2011","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2021.03.079_b2345","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.vaccine.2011.10.104","article-title":"Lack of association between childhood immunizations and encephalitis in California, 1998\u20132008","volume":"30","author":"Pahud","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2350","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa1012952","article-title":"Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil","volume":"364","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b2355","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1016\/j.vaccine.2012.03.030","article-title":"Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population","volume":"30","author":"Phua","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2360","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1086\/431511","article-title":"Evaluation of RIX4414, A live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants","volume":"192","author":"Phua","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b2365","doi-asserted-by":"crossref","first-page":"6592","DOI":"10.1016\/j.vaccine.2011.06.112","article-title":"Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15\u201359 years of age","volume":"29","author":"Ray","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2370","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/cit045","article-title":"Neonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age birth","volume":"56","author":"Richards","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b2375","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4161\/hv.18865","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 AS04-adjuvanted vaccine: Up to 8.4 years of follow-up","volume":"8","author":"Roteli-Martins","year":"2012","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b2380","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/aje\/kws011","article-title":"Immunization and bell's palsy in children: A case-centered analysis","volume":"175","author":"Rowhani-Rahbar","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2385","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa052434","article-title":"Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis","volume":"354","author":"Ruiz-Palacios","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b2390","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJM199106203242503","article-title":"The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex","volume":"324","author":"Santosham","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b2395","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b2400","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jadohealth.2011.11.004","article-title":"Four-year follow-up of the immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10\u201314 years","volume":"50","author":"Schwarz","year":"2012","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2021.03.079_b2405","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jama.2012.97","article-title":"Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants","volume":"307","author":"Shui","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.03.079_b2410","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/INF.0b013e3181c38f3b","article-title":"Phase I\/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents","volume":"29","author":"Siberry","year":"2010","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b2415","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-152-9-201005040-00004","article-title":"Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial","volume":"152","author":"Simberkoff","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b2420","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1503\/cmaj.091891","article-title":"Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study","volume":"182","author":"Siriwardena","year":"2010","journal-title":"CMAJ Can Med Assoc J"},{"key":"10.1016\/j.vaccine.2021.03.079_b2425","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/infdis\/jis619","article-title":"Safety and immunogenicity of human papillomavirus-16\/18 AS04-adjuvanted vaccine: a randomized trial in 10\u201325-year-old HIV-Seronegative African girls and young women","volume":"207","author":"Sow","year":"2013","journal-title":"J Infect Dis"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2021.03.079_b2430","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1086\/653550","article-title":"Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants","volume":"202","author":"Steele","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b2435","doi-asserted-by":"crossref","first-page":"9467","DOI":"10.1016\/j.vaccine.2011.10.029","article-title":"Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: A database study","volume":"29","author":"Stowe","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2440","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jama.2012.165","article-title":"Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and haemophilus influenzae type b","volume":"307","author":"Sun","year":"2012","journal-title":"Jama-J Am Med Assoc"},{"key":"10.1016\/j.vaccine.2021.03.079_b2445","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1086\/656601","article-title":"A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults","volume":"202","author":"Talaat","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b2450","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/lary.22471","article-title":"Case-control study of risk factors for spasmodic dysphonia: A comparison with other voice disorders","volume":"122","author":"Tanner","year":"2012","journal-title":"Laryngoscope"},{"key":"10.1016\/j.vaccine.2021.03.079_b2455","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/j.1399-3038.2010.01018.x","article-title":"Early childhood infections and immunisation and the development of allergic disease in particular asthma in a high-risk cohort: A prospective study of allergy-prone children from birth to six years","volume":"21","author":"Thomson","year":"2010","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2460","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/jech.2009.092296","article-title":"The effect of influenza vaccination on the incidence of chronic obstructive pulmonary disease exacerbations in the immediate postvaccination period","volume":"65","author":"Ting","year":"2011","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.vaccine.2021.03.079_b2465","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/pds.3220","article-title":"The risk of Guillain-Barre syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009\u20132010 seasonal influenza vaccines: results from self-controlled analyses","volume":"21","author":"Tokars","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2021.03.079_b2470","doi-asserted-by":"crossref","first-page":"7733","DOI":"10.1016\/j.vaccine.2011.07.128","article-title":"Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok[REGISTERED]) against influenza in healthy adults: a randomized, placebo-controlled trial","volume":"29","author":"Treanor","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2475","doi-asserted-by":"crossref","unstructured":"Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM, Group VSDRCAIW. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine. 2012;30:2024-31.","DOI":"10.1016\/j.vaccine.2012.01.027"},{"key":"10.1016\/j.vaccine.2021.03.079_b2480","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1365-2796.2011.02474.x","article-title":"Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study","volume":"271","author":"Tseng","year":"2012","journal-title":"J Intern Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b2485","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1001\/jama.2010.529","article-title":"Pneumococcal vaccination and risk of acute myocardial infarction and stroke in men","volume":"303","author":"Tseng","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.03.079_b2490","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1016\/j.vaccine.2012.01.093","article-title":"The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: The first case-control study in Asia","volume":"30","author":"Uno","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2495","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/INF.0b013e318253add3","article-title":"Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico","volume":"31","author":"Velazquez","year":"2012","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b2500","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/pds.3321","article-title":"Risk of Guillain-Barre syndrome after meningococcal conjugate vaccination","volume":"21","author":"Velentgas","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2021.03.079_b2505","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.vaccine.2011.11.096","article-title":"Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults >=60 years of age","volume":"30","author":"Vermeulen","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2510","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1016\/j.vaccine.2006.03.025","article-title":"Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants","volume":"24","author":"Vesikari","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2515","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.vaccine.2011.01.004","article-title":"Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2520","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/j.vaccine.2004.01.044","article-title":"Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants","volume":"22","author":"Vesikari","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2525","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/01.inf.0000141722.10130.50","article-title":"Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants","volume":"23","author":"Vesikari","year":"2004","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b2530","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa052664","article-title":"Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine","volume":"354","author":"Vesikari","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b2535","article-title":"Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS ONE [Electronic Resource]"},{"key":"10.1016\/j.vaccine.2021.03.079_b2540","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4161\/hv.6.4.10654","article-title":"Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults","volume":"6","author":"Weinberg","year":"2010","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2021.03.079_b2545","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1469-8749.2011.03915.x","article-title":"No association between early gastrointestinal problems and autistic-like traits in the general population","volume":"53","author":"Whitehouse","year":"2011","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2550","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027897","article-title":"Adverse events following 12 and 18 month vaccinations: a population-based, self-controlled case series analysis","volume":"6","author":"Wilson","year":"2011","journal-title":"PLoS ONE [Electronic Resource]"},{"key":"10.1016\/j.vaccine.2021.03.079_b2555","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/aje\/kws196","article-title":"Guillain-barre syndrome during the 2009\u20132010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million americans","volume":"175","author":"Wise","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2560","doi-asserted-by":"crossref","DOI":"10.1002\/pds.3301","article-title":"Assessing the effect of vaccine on spontaneous abortion using time-dependent covariates Cox models","author":"Xu","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2021.03.079_b2565","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/aje\/kws197","article-title":"Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the post-licensure rapid immunization safety monitoring (PRISM) system, 2009\u20132010","volume":"175","author":"Yih","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.03.079_b2570","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/pds.1354","article-title":"Hepatitis B vaccine and risk of autoimmune thyroid disease: A vaccine safety datalink study","volume":"16","author":"Yu","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2021.03.079_b2575","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.vaccine.2008.12.059","article-title":"Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age","volume":"27","author":"Zaman","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2580","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.03.079_b2585","doi-asserted-by":"crossref","first-page":"e1499","DOI":"10.1542\/peds.2010-1240","article-title":"Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization","volume":"126","author":"Christie","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.03.079_b2590","unstructured":"EU\/EEA EO. Study to evaluate the efficacy, safety and immunogenicity of two or three doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. http:\/\/wwwwhoint\/trialsearch\/Trial2aspx?TrialID=EUCTR2015-001485-26-Outside-EU\/EEA. 2015."},{"key":"10.1016\/j.vaccine.2021.03.079_b2595","unstructured":"EU\/EEA EO. A phase III study to assess the efficacy, immunogenicity and safety of GSK Biologicals\u2019 human rotavirus (HRV) vaccine given concomitantly with routine expanded program on immunisation (EPI) vaccinations including oral poliovirus vaccine (OPV) in healthy infants across 6 countries in Latin America. http:\/\/wwwwhoint\/trialsearch\/Trial2aspx?TrialID=EUCTR2015-001540-10-Outside-EU\/EEA. 2015."},{"key":"10.1016\/j.vaccine.2021.03.079_b2600","unstructured":"Euctr Outside EU\/EEA. A phase II study to assess the safety and immunogenicity of GlaxoSmithKline Biologicals\u2019 rotavirus vaccine, RIX4414 when administered to HIV infected infants in South Africa. http:\/\/wwwwhoint\/trialsearch\/Trial2aspx?TrialID=EUCTR2015-001484-39-Outside-EU\/EEA; 2015."},{"key":"10.1016\/j.vaccine.2021.03.079_b2605","unstructured":"Euctr Outside EU\/EEA. Study to evaluate the efficacy and safety of two doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants; 2015."},{"key":"10.1016\/j.vaccine.2021.03.079_b2610","unstructured":"Euctr Outside EU\/EEA. Study to evaluate immunogenicity, reactogenicity and safety of Rotarix\u2122 vaccine in Korean infants. http:\/\/wwwwhoint\/trialsearch\/Trial2aspx?TrialID=EUCTR2015-001545-81-Outside-EU\/EEA; 2015."},{"key":"10.1016\/j.vaccine.2021.03.079_b2615","unstructured":"Euctr Outside EU\/EEA. Study to evaluate the efficacy and safety of two doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants. http:\/\/wwwwhoint\/trialsearch\/Trial2aspx?TrialID=EUCTR2015-001541-92-Outside-EU\/EEA; 2015."},{"key":"10.1016\/j.vaccine.2021.03.079_b2620","unstructured":"GlaxoSmithKline. A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants. https:\/\/ClinicalTrials.gov\/show\/NCT00197210; 2003."},{"key":"10.1016\/j.vaccine.2021.03.079_b2625","unstructured":"GlaxoSmithKline. Study of 2 Doses of HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants; 2003."},{"key":"10.1016\/j.vaccine.2021.03.079_b2630","unstructured":"GlaxoSmithKline. Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210). https:\/\/ClinicalTrials.gov\/show\/NCT00329745; 2007."},{"key":"10.1016\/j.vaccine.2021.03.079_b2635","unstructured":"GlaxoSmithKline Biologicals. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants 2015."},{"key":"10.1016\/j.vaccine.2021.03.079_b2640","unstructured":"GlaxoSmithKline Biologicals. Study to evaluate immunogenicity, reactogenicity and safety of Rotarix\u2122 vaccine in Korean infants. http:\/\/wwwwhoint\/trialsearch\/Trial2aspx?TrialID=EUCTR2015-001545-81-Outside-EU\/EEA; 2015."},{"key":"10.1016\/j.vaccine.2021.03.079_b2645","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/INF.0b013e31814521cb","article-title":"Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants","volume":"26","author":"Goveia","year":"2007","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b2650","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/INF.0b013e3182435afe","article-title":"Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children","volume":"31","author":"Grant","year":"2012","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b2655","unstructured":"Guillermo M, al. e. RIX4414 (Rotarix\u2122) has demonstrated efficacy during the first 2 years of life in infants from 11 Latin American countries. 10th International Rotavirus Symposium (IRS). Bangkok, Thailand2012."},{"key":"10.1016\/j.vaccine.2021.03.079_b2660","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/INF.0000000000002281","article-title":"Rotavirus vaccination does not increase type 1 diabetes and may decrease celiac disease in children and adolescents","volume":"38","author":"Hemming-Harlo","year":"2019","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2021.03.079_b2665","doi-asserted-by":"crossref","first-page":"A61","DOI":"10.1016\/j.vaccine.2011.09.026","article-title":"Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq([REGISTERED]), in Kenya, including among HIV-infected and HIV-exposed infants","volume":"30","author":"Laserson","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2670","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/j.vaccine.2013.03.001","article-title":"Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial","volume":"31","author":"Lau","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2675","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/sim.5911","article-title":"Fractional polynomial adjustment for time-varying covariates in a self-controlled case series analysis","volume":"33","author":"Lee","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b2680","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b2685","doi-asserted-by":"crossref","unstructured":"Phua KB, al. e. Human rotavirus vaccine RIX4414 (Rotarix\u2122) is highly efficacious in infants from Asia during the first two years of life. 13th International Congress on Infectious Diseases (ICID). Kuala Lumpur, Malaysia; 2008.","DOI":"10.1016\/j.ijid.2008.05.370"},{"key":"10.1016\/j.vaccine.2021.03.079_b2690","doi-asserted-by":"crossref","unstructured":"Phua KB, al. e. Human rotavirus vaccine RIX4414 (Rotarix\u2122) is highly efficacious in Asian infants during the first three years of life. 13th Asian Pacific Congress of Pediatrics (APCP). Shanghai, China; 2009.","DOI":"10.1016\/j.ijid.2008.05.370"},{"key":"10.1016\/j.vaccine.2021.03.079_b2695","doi-asserted-by":"crossref","unstructured":"Phua KB, al. e. Human rotavirus vaccine RIX4414 is highly efficacious in Asian infants during the third year of life. 27th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Brussels, Belgium; 2009.","DOI":"10.1016\/j.ijid.2008.05.370"},{"key":"10.1016\/j.vaccine.2021.03.079_b2700","unstructured":"Phua KB, al. e. Efficacy of rotavirus vaccine RIX4414 during the first 3 years of life: a randomised, double-blind, placebo-controlled study in infants from Hong Kong, Singapore and Taiwan. 10th International Rotavirus Symposium (IRS). Bangkok, Thailand; 2012."},{"key":"10.1016\/j.vaccine.2021.03.079_b2705","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1016\/j.vaccine.2009.07.098","article-title":"Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study","volume":"27","author":"Phua","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2710","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1080\/21645515.2018.1502517","article-title":"A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL)","volume":"14","author":"Popmihajlov","year":"2018","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.03.079_b2715","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.inf.0000254391.71103.e8","article-title":"Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States","volume":"26","author":"Rodriguez","year":"2007","journal-title":"Pediatric Infect Dis J"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2021.03.079_b2720","doi-asserted-by":"crossref","first-page":"A71","DOI":"10.1016\/j.vaccine.2011.11.094","article-title":"Efficacy of the oral pentavalent rotavirus vaccine in Mali","volume":"30","author":"Sow","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2725","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1097\/INF.0b013e3182138278","article-title":"Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America","volume":"30","author":"Tregnaghi","year":"2011","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.03.079_b2730","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(10)60755-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Zaman","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2021.03.079_b2735","doi-asserted-by":"crossref","first-page":"A94","DOI":"10.1016\/j.vaccine.2011.07.117","article-title":"Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh","volume":"30","author":"Zaman","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.079_b2740","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S1473-3099(20)30130-4","article-title":"The state of vaccine safety science: systematic reviews of the evidence","volume":"20","author":"Dudley","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.079_b2745","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12458","article-title":"Association between rotavirus vaccination and risk of intussusception among neonates and infants: a systematic review and meta-analysis","volume":"2","author":"Lu","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.vaccine.2021.03.079_b2750","unstructured":"Health Resources and Services Administration. Vaccine Injury Table."},{"key":"10.1016\/j.vaccine.2021.03.079_b2755","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/M13-0480","article-title":"Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications","volume":"160","author":"Hartung","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b2760","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12916-015-0430-4","article-title":"Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles","volume":"13","author":"Tang","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2021.03.079_b2765","unstructured":"HealthIT.gov. Interoperability Proving Ground."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21003856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21003856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:59:04Z","timestamp":1759402744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21003856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":553,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0264410X21003856"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.03.079","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.03.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}